

## CURRICULUM VITAE

**Ronald T. Acton, PhD, HCLD(ABB), CC(ABB), D(ABMLI), MB(ASCP)<sup>CM</sup>**

**Birth Date:** 10/19/41    **Birthplace:** Birmingham, Alabama    **Nationality:** USA

### **Education:**

**Undergraduate:** Birmingham-Southern College, Birmingham, Alabama, A.B., 1965.

**Graduate:** University of Alabama at Birmingham, Birmingham, Alabama, Ph.D., 1970  
Professor E. E. Evans, Ph.D., Mentor.

University of Alabama at Birmingham, Birmingham, Alabama, 1991-1992  
Professor Wayne H. Finley, Ph.D., M.D., Program Director of Medical Genetics.

**Postdoctoral Training:** Research Fellow, Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama. Professor J. Claude Bennett, M.D., Mentor, 1969-1970.

Microbiology Technologist, Baptist Medical Center, Montclair, Birmingham, Alabama, Claire Elliott, M.D., Supervisor, 1969 – 1970.

Research Fellow, Division of Biology, California Institute of Technology, Pasadena, California. Professor Ray D. Owen, Ph.D., Mentor, 1970-1972.

Special Fellow, MRC Immunochemistry Unit, Department of Biochemistry, University of Oxford, Oxford, England, Professor R.R. Porter, Ph.D., Mentor, 1972-1973.

**Certification:** Diplomate: American Board of Medical Laboratory Immunology, No. 72, 1985 - 2010. Emeritus Diplomate, 2011.

High Complexity Clinical Laboratory Director: American Board of Bioanalysis, No. 6400, 1993.

Certified Laboratory Specialist in Molecular Biology, National Certification Agency for Medical Laboratory Personnel, 1997. No. 702. Renamed Technologist in Molecular Biology, MB(ASCP)<sup>CM</sup> by the American Society of Clinical Pathology, August 2010. Recertified 01/14/20120.

Clinical Consultant: American Board of Bioanalysis, NO. 6400, 2012.

**Professional Career:** Professor Emeritus in the School of Medicine, Department of Microbiology  
University of Alabama at Birmingham April 7, 2017.

Adjunct Professor, Department of Microbiology, University of Alabama at  
Birmingham, Birmingham, AL, October 1, 2007 – 2017.

Research Associate, Southern Iron Disorders Center, Birmingham, Alabama,  
October 1, 2007 – present.

Professor of Genetics, University of Alabama at Birmingham, Birmingham,  
AL, 2003 – 2007.

Consultant, Medical Genomics Laboratory, Department of Genetics, University  
of Alabama at Birmingham, 2003 - 2007.

Senior Scientist, Clinical Nutrition Research Center, University of Alabama  
at Birmingham, Alabama, 2000 – 2007.

Co-Director and Co-Founder, Familial Cancer Clinic, University of Alabama  
Health Systems, Birmingham, AL, 1997 – 2003.

Professor of Medicine, University of Alabama at Birmingham, Birmingham,  
Alabama, 1982 – 9/30/2007.

Director, Immunogenetics Program, Department of Microbiology and  
Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 1982  
– 9/30/2007.

Director and Founder, Immunogenetics/DNA Diagnostic Laboratory,  
Department of Medicine, University of Alabama Health Services Foundation,  
1982 – 2003.

Deputy Director, Diabetes Research and Training Center, University of  
Alabama at Birmingham, Birmingham, AL 1979-1984.

Co-Director, Diabetes Outpatient Clinical Laboratory, Division of  
Endocrinology and Metabolism, Department of Medicine, University of  
Alabama at Birmingham, Birmingham, Alabama, 1979-1985.

Professor of Microbiology, University of Alabama at Birmingham, Birmingham,  
Alabama, 1978 – 9/30/2007.

Professor of Epidemiology, School of Public Health, University of Alabama at  
Birmingham, Birmingham, Alabama, 1978 – 9/30/2007.

Senior Scientist/Associate Member, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, 1978 – 9/30/2007.

Senior Scientist, Multipurpose Arthritis Center, University of Alabama at Birmingham, Birmingham, Alabama, 1978 – 9/30/2007.

Associate Director for Research, Diabetes Research and Training Center, University of Alabama at Birmingham, Birmingham, Alabama, 1977-1979.

Senior Scientist, Diabetes Research and Training Center, University of Alabama at Birmingham, Birmingham, Alabama, 1977 – 9/30/2007.

Senior Scientist, Center for Aging, University of Alabama at Birmingham, Birmingham, Alabama, 1984 – 9/30/2007.

Program Director, Multidisciplinary Training Program in Tumor Biology, 1977 – 1994.

Coordinator, Comprehensive Cancer Center, Tissue Culture Core Facility, University of Alabama at Birmingham, 1974 – 1981.

Program Director, Pathology of Membranes and Organelles Postdoctoral Training Program, University of Alabama at Birmingham, 1974 – 1980.

Director, Cell Culture Center, University of Alabama at Birmingham, 1974 – 1979.

Associate Professor of Microbiology, University of Alabama at Birmingham, 1975 – 1978.

Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, 1975 – 1978.

Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, 1973 – 1975.

Assistant Professor of Microbiology, University of Alabama at Birmingham, 1972 – 1975.

Graduate Trainee, Department of Microbiology, University of Alabama, 1965 - 1969.

Research Assistant, Department of Microbiology, University of Alabama at Birmingham, 1965.

**Awards:**

USPHS Graduate Trainee, 1965 – 1969.

First Place, Sigma Xi (Birmingham Chapter) Graduate Student Research Competition, 1967.

President's Award for Graduate Research of the Southeastern Branch of the Society of American Microbiology, 1967.

First Place, Graduate Research Achievement, Alabama Academy of Science, 1968.

Finalist, Sigma Xi (Birmingham Chapter) Graduate Student Research Competition, 1968.

Second Place, Sigma Xi (Birmingham Chapter) Graduate Student Research Competition, 1969.

Smith Kline and French Research Fellow, 1970 – 1972.

Special Fellow, Leukemia Society of America, 1972 – 1973.  
Established Investigator, American Heart Association, 1973-1978.

Outstanding Young Men of America, 1974.

Third Place Abstract Winner, Samuel L. Kountz International Symposium on Renal Disease and Transplantation in Blacks, 1993.

Fellow, Association of Medical Laboratory Immunologists, 1999.

Fellow, American Academy of Microbiology, 2000.

**Societies:**

American Association of Immunologists. Emeritus.

American Society of Biochemistry and Molecular Biology

American Society for Histocompatibility and Immunogenetics

American Society of Human Genetics

American Society for Microbiology

**UAB Committees:**

Member, Biohazard Committee, UAB, 1973 – 1982.

Member, Committee on Department of Microbiology Organizational Development, 1974 – 1975.

Member, Concepts II Executive Teaching Committee of the School of Medicine, UAB, 1974 - 1975.

Chairman, Cell Culture Congress Organizing Committee, UAB, 1974 – 1975.

Member, Microbiology Graduate Exam Committee, UAB, 1974 – 1975.

Member, Microbiology School of Medicine Teaching Committee, 1975 – 1976.

Member, The Joint Faculty Status Committee, UAB, 1975 – 1977.

Member, Animal Services Petition Committee, Department of Microbiology, 1976.

Member, Microbiology Committee on Patents, UAB, 1976.

Member, Committee on the Local Status of Clinical Immunology, UAB, 1976.

Chairman, Microbiology Committee for Extramural Affairs, UAB, 1976 – 1978.

Member, Aging Training Grant Review Committee, 1977 – 1983.

Member, Executive Committee, Diabetes Research and Training Center, 1977 – 1984.

Member, UAB Cell Culture Center Use Committee, 1977 – 1985.

Member, Scientific Review Committee, Diabetes Research and Training Center, 1978.

Member, Space Committee, Diabetes Research and Training center, 1978 – 1980.

Member, Pediatric Oncology Group, 1980 – 1985.

Member, Research Subcommittee of Self Evaluation Steering Committee for School of Public Health, 1981.

Chairman, Promotion Committee, Department of Microbiology, 1981-1983.

Member, Molecular Cellular Biology Graduate Admissions Committee, 1985 - 1987.

Member, Advisory Council, Center for International Programs UAB, 1987 -1990.

Member, Correlated Basic Medical Science Curriculum Committee of the School of Medicine, UAB, 1993 – 1994.

Member, Cancer Research and Training Center Review Committee, UAB, 1993-1997.

Member, Committee for the Creation of a Doctoral Level Graduate Training Program in Forensic Science, 1995 – 1996.

Member, Molecular and Clinical Genetics Review Committee, 1996 – 1998.

Member, LCME Self-Study Committee, 1997 – 1998.

Member, Microbiology Faculty Promotions Committee, 1996 – 2000.

Member, Microbiology Research Priorities Committee, 1996 – 2000.

Member, Human Genetics Search Committee, 1997-2000.

Member, School of Medicine Basic Science Promotions Committee, 1995 - 2001.

Course Master Sophomore Medical Microbiology, 1995 – 2000.

Member, Integrated Medical Sciences Subcommittee, 1996 – 2001.

Member, Scientific Review Committee, Diabetes Trust Fund, 1998 – 2001.

Member, Committee on Graduate Study in Forensic Science, 1996 – 2004.

Member, Faculty Council, School of Medicine, 1999- 2003.

Member, The Deep South Center for Minority and Rural Health Improvement, 2001 – 2007.

Member, School of Medicine Medical Student Academic Standing and Promotions Committee, 2002 – 2005.

Member, UASOM Admissions Interview Committee, 2002 – 2018.

Member, UASOM Admissions Executive Committee, 2005 – 2018.

Member, UASOM Admissions Selection Committee, 2007 – 2018.

Member, Microbiology Faculty Promotions Committee, 2004 – 2005.

Member, UASOM Faculty Development Committee, 2006 – 2007.

**Other Committees** Chairman, Organization Committee, 2<sup>nd</sup> International Cell Culture Congress, 1981.

Member, Cancer Center Support Grant Review Committee, NIH, 1978 – 1982.

NIH - Ad Hoc Reviewer, 1982 – 2007.

Member, Ad Hoc Cancer Construction Review Committee, NIH, 1984, 1985.

Member, Governor's Committee on Physical Fitness, 1988 – 1991.

Member, American Society for Histocompatibility and Immunogenetics, Quality Assurance/Standards Subcommittee for Molecular Testing, 1988 – 1993.

Board of Directors, Society of Prospective Medicine, 1989 – 1992.

Member, CDC Expert Panel on Hemochromatosis, 2000- 2002.

Board of Directors, University of Alabama at Birmingham Retirees Association, 2012 – 2015.

President, Board of Directors, University of Alabama at Birmingham Retirees Association, 2013 – 2014.

**Consultantships** Heriff Company, 1979 - 1981.

Technicon Instruments Corp., 1978 – 1982.

Energy Service Company, 1973 – 1988.

NASA, Separation Processes Branch, George C. Marshall Space Flight Center, 1977 – 1979.

Fermentation Design, Inc., 1974 – 1977.

Monsanto Company, New Enterprise Division, 1976 – 1977.

American Registry of Pathology, Armed Forces DNA Identification Laboratory, 2011.

Consultant/Expert Witness: Use of genetic marker and DNA testing in paternity, forensic and civil cases. Testified as an expert in Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Minnesota, Mississippi, Montana, North Carolina, Oklahoma, Tennessee, Texas, Virginia, Washington, and Wisconsin.

**Research Funding** Research activities over a period of 35 years were funded by the NIH, NSF and various private foundations. The amount of peer reviewed funding exceeded one million dollars for several years during this period.

**Editorships:** Developmental and Comparative Immunology Journal, 1974 – 1979.  
MSS Information Corporation Series on Immunology and Medicine - 40 books edited, 1972 – 1975.

Pediatric Oncology, Vol 1, 1981; Vol. 2, 1982; Vol 3, 1983.

Sport & Medicina, 1985 – 2000.

Scienza Veterinaria, E Biologia Animale, 1986 – 2000.

**Other Activities:** Private Pilot 1969 – present.

Health Promotion Services, Inc., President 1980 – 1985.

South Arising Consultants – President.

South Arising Vintage Autos – President.

Civil Air Patrol, Captain, 1969 - 1975, Senior Member, 1997 – 2014.

Board of Directors, Creative Schools, Inc., 1974.

Vice President, Birmingham Track Club, 1980.

Coach, Birmingham Track Club Master Team, 1980 – 1982.

Officer at Large, Alabama Wheelmen, 1987 - 1988, 1990.

President, Alabama Wheelmen, 1989.

President, Magic City Boppers, 1995 – 1996.

Board of Directors, Top of the Gulf Condominium Association, 2015 – 2016.

### **Publications**

1. **Acton RT**, Evans EE. Comparative immunological studies with the oyster, *Crassostrea virginica*. Vitro. 3:139-145, 1968.
2. Evans EE, Legler DW, Painter B, **Acton RT**, Attleberger M. Complement-dependent systems and the phylogeny of immunity. Vitro. 3:146-153, 1968.



3. **Acton RT**, Evans EE. Bacteriophage clearance in the oyster, *Crassostrea virginica*. J Bacteriol. 95:1260-1266, 1968.
4. Evans EE, Painter B, Evans ML, Weinheimer P, **Acton RT**. An induced bactericidin in the spiny lobster, *Panulirus argus*. Proc Soc Exp Biol Med. 128:394-398, 1968.
5. Sigel MM, **Acton RT**, Evans EE, Russel W, Wells TG, Painter B, Lucas AH. T2 bacteriophage clearance in the lemon shark. Proc Soc Exp Biol. Med. 128:977-979, 1968.
6. **Acton RT**, Evans EE, Bennett JC. Immunological capabilities of the oyster, *Crassostrea virginica*. Comp Biochem Physiol. 29:149-160, 1969.
7. Weinheimer PF, **Acton RT**, Evans EE. An attempt to induce a bactericidal response in the oyster. J Bacteriol. 97:462-463, 1969.
8. Weinheimer PF, Evans EE, Stroud RM, **Acton RT**, Painter B. Comparative Immunology: Natural Hemolytic System of the Spiny Lobster, *Panulirus argus* Proc Soc Exp Biol Med. 130:322-326, 1969.
9. Evans EE, Weinheimer PF, Painter B, **Acton RT**, Evans ML. Secondary and tertiary responses of the induced bactericide from the West Indian spiny lobster, *Panulirus argus*. J Bacteriol. 98:943-946, 1969.
10. Weinheimer PF, **Acton RT**, Evans EE. Specificity of the induced bactericidin of the West Indian spiny lobster, *Panulirus argus*. J Bacteriol. 98:947-948, 1969.
11. **Acton RT**, Weinheimer PF, Evans EE. A bactericidal system in *Panulirus argus*. J Invert Pathol. 13:463-464, 1969.
12. Evans EE, Weinheimer PF, **Acton RT**, Cushing JE. Induced bactericidal response in a *Panulirus argus*. Nature. 223:695, 1969.
13. **Acton RT**, Bennett JC, Evans EE, Schrohenloher RE. Physical and chemical characterization of an oyster hemagglutinin. J Biol Chem. 244:4128-4135, 1969.
14. Legler DW, Evans EE, Weinheimer PF, **Acton RT**, Attleberger MH. Immunoglobulin and complement systems in amphibian serum. Biology of Amphibian Tumors. Springer-Verlag, New York, 169-176, 1969.
15. **Acton RT**, Weinheimer PF, Hildemann WJ, Evans EE. Induced bactericidal response in the hagfish. J Bacteriol. 99:626-628, 1969.
15. Evans EE, Cushing JE, Sawyer S, Weinheimer PF, **Acton RT**, McNeely JL. Induced bactericidal response in the California spiny lobster, *Panulirus interruptus*. Proc Soc Exp Biol Med. 132:111-114, 1969.

17. Cooper EL, **Acton RT**, Weinheimer PF, Evans EE. Lack of a bactericidal response in the earthworm, *Lumbricus terrestris*, after immunization with bacterial antigens. J Invert Path. 14: 402-406, 1969.
18. **Acton RT**. Immunobiological and Immunochemical studies of the oyster, *Crassostrea virginica*, 1 -134. Ph.D. Dissertation, University of Alabama at Birmingham, Birmingham, Alabama, 1970.
19. Evans EE, **Acton RT**, Bennett JC, Weinheimer PF. Evolution of the immune response. Protides of the Biological Fluids, Pergamon Press, Oxford, England. Vol 17:29 - 38, 1970.
20. Weinheimer PF, **Acton RT**, Cushing JE, Evans EE. Reactions of sipunculid coelomic fluid with erythrocytes. Life Sciences 9:145-152, 1970.
21. **Acton RT**, Weinheimer PF, Wolcott M, Evans EE, Bennett JC. N-terminal sequences of immunoglobulin heavy and light chains from three species of lower vertebrates. Nature. 228: 991-992, 1970.
22. **Acton RT**, Weinheimer PF, Hall SJ, Neidermeier W, Shelton E, Bennett JC. Tetrameric immune macroglobulins in three orders of bony fishes. Proc Nat Acad Sci. 68:107-111, 1971.
23. Weinheimer PF, Evans EE, **Acton RT**. Comparative immunology: the hemolytic complement system of the anuran amphibian *Bufo marinus*. Com. Biochem Physiol. 38A:483-488, 1971.
24. Legler DW, **Acton RT**, Weinheimer PF, Dupree HK. Humoral antibody responses in the gar, *Lepisosteus osseus*. Immunology. 20:1009-1017, 1971.
25. Legler DW, Weinheimer PF, **Acton RT**, Dupress HK, Russell TR. Humoral immune factors in the paddlefish, *Polyodon spathula*. Comp Biochem Physiol. 38B:523-527, 1971.
26. **Acton RT**, Weinheimer PF, Dupree HK, Evans EE, Bennett JC. Phylogeny of Immunoglobulins: Characterization of a 14S antibody from the gar, *Lepisosteus osseus*. Biochemistry. 10:2028-2036, 1971.
27. Neidermeier W, Kirkland T, **Acton RT**, Bennett JC. The carbohydrate composition of immunoglobulins G. Biochemica et Biophysica Acta. 237:442-449, 1971.
28. **Acton RT**, Weinheimer PF, Hildemann WH, Evans EE. Bactericidal antibody response in the Pacific hagfish, *Eptatretus stoutii*. Infect Immunity. 4:160-166, 1971.
29. Johnston WJ, Jr, **Acton RT**, Weinheimer PF, Niedermeier, W, Evans EE, Shelton E, Bennett JC. Isolation and physiochemical characterization of an "IgM" - like antibody from the stingray, *Dasyatis americana*. J Immunol. 107:782-793, 1971.
30. Weinheimer PF, Mestecky J, **Acton RT**. Species distribution of J chain. J Immunol. 107: 1211-1212, 1971.

31. **Acton RT**, Weinheimer PF, Depree HK, Russell RR, Wolcott M, Evans EE, Bennett JC. Isolation and characterization of the immune macroglobulin from the paddlefish, *Polyodon spathula*. *J Biol Chem.* 246(22):6760-9, 1971.
32. **Acton RT**, Evans EE, Weinheimer PF, Shelton E, Niedermeier W, Bennett JC. Phylogeny of immunoglobulins: Purification and physicochemical characterization of the immune macroglobulin from the turtle, *Pseudemus scripta*. *Immunochemistry* 9:421-433, 1972.
33. **Acton RT**, Evans EE, Weinheimer PF, Niedermeier W, Bennett JC. Purification and characterization of two classes of immunoglobulins from the marine toad, *Bufo marinus*. *Biochemistry* 11:2751-2759, 1972.
34. Acton RT, Neidermeier W, Weinheimer PF, Clem LW, Leslie GA, Bennett JC. The carbohydrate composition of immunoglobulins from diverse species of vertebrates. *J Immunol.* 109:371-381, 1972.
35. **Acton RT**. Cell surfaces: Cell interactions. *Comparative Molecular Biology of Extracellular Matrices*. HC Slavin, (ed.) Academic Press, New York 127-134, 1972.
36. **Acton RT**, Weinheimer PF, Niedermeier W. The carbohydrate composition of invertebrate hemmagglutinin subunits isolated from the lobster, *Panulirus argus* and the oyster, *Crassostrea virginica*. *Com. Biochem Physiol.* 44B:185-189, 1973.
37. Hall SJ III, Evans EE, Dupree HK, **Acton RT**, Weinheimer PF, Bennett JC. Characterization of teleostean immunoglobulins. The immune macroglobulin from the channel catfish, *Ictalurus punctatus*. *Comp. Biochem. Physiol.* 46B: 187-197, 1973
38. **Acton RT**, Blankenhorn EP, Douglas TC, Owen RD, Hilgers J, Hoffman HA, Boyse EA. Variation among sublines of inbred AKR mice. *Nature New Biology.* 245:810, 1973.
39. **Acton RT**, Weinheimer PF. Hemagglutinins: Primitive receptor molecules operative in invertebrates defense mechanisms. *Contemporary Topics in Immunobiology*, Plenum Press, New York. Vol 4:271-282, 1974.
40. **Acton RT**, Theodor JL. Primitive recognition systems. L Brent, J Hollorow (eds) *Progress in Immunology*. North Holland Publishing Co., Vol 2:287-291, 1974.
41. **Acton RT**, Morris RJ, Williams AF. Estimation of the amount and tissue distribution of rat Thy-1.1 antigen. *Eur J Immunology* 4:598-602, 1974.
42. Muirhead ML, **Acton RT**, Williams AF. Preliminary characterization of Thy-1.1 and Ag-B antigens from rat tissues solubilized in detergents. *Biochem J.* 143:51-61, 1974.
43. Zwerner RK, Runyan C, Cox RM, Lynn JD, **Acton RT**. An evaluation of suspension culture systems for the growth of murine lymphoblastoid lines expressing TL and Thy-1 alloantigens. *Biotec Bioeng.* 17:629-657, 1975.

44. Lynn JD, **Acton RT**. Design of a large-scale mammalian cell suspension culture facility. *Biotech Bioeng.* 17:659-673, 1975.
45. Zwerner RK, **Acton RT**. Growth properties and alloantigenic expression of murine lymphoblastoid cell lines. *J Exp Med.* 142:378-390, 1975.
46. Neidermeier W, Tomana M, Lynn JD, **Acton RT**. Production and chemical characterization of cell membrane glycoproteins. *Ala J Medical Sciences.* 14:66-175, 1977.
47. Barstad PA, Henley SL, Cox RM, Lynn JD, **Acton RT**. Production of milligram quantities of H-2K and Thy-1 alloantigens by large-scale mammalian cell culture. *Proc Soc Exp Biol Med.* 155:296-300, 1977.
48. **Acton RT**, Lynn JD. Description and operation of a large-scale, mammalian cell, suspension culture facility. *Adv Biochem Eng.* 7:85-110, 1977.
49. Zwerner RK, Barstad PA, **Acton RT**. Isolation and characterization of murine cell surface components. I. Purification of milligram quantities of Thy-1.1. *J Exp.Med.* 146:986-1000, 1977.
50. Zwerner RK, **Acton RT**, Seeds NW. The developmental appearance of Thy-1 in mouse reaggregating brain cell cultures. *Develop Biol.* 60:331-335, 1977.
51. **Acton RT**, Barstad PA, Cox RM, Zwerner RK, Wise KS, Lynn JD. Large scale production of murine lymphoblastoid cell lines expressing differentiation alloantigens. *Cell culture and its application.* (Acton RT and Lynn JD, eds.) 129-160, Academic Press, New York, 1977.
52. Barstad P, Zwerner R, **Acton R**. Partial purification of H-2K molecules from large-scale cell culture. *Protides of Biological Fluids* (H Peeters, Ed), Vol 25, 637-640, Pergamon Press, Oxford, 1977.
53. Zwerner R, Barstad P, **Acton R**. Structural and functional aspects of the murine Thy-1.1 differentiation antigen. *Protides of Biological Fluids* (H Peeters, ed) Vol. 25, 661-664, Pergamon Press, Oxford, 1977.
54. Wise K, **Acton R**. Endogenous virus antigens of murine lymphoblastoid cell lines. *Protides of Biological Fluids.* 707-714, Pergamon Press, Oxford 1977.
55. **Acton RT**, Addis JBL, Carl GF, McClain LD, Bridgers WF. The association of Thy-1 differentiation alloantigen with synaptic complexes isolated from mouse brain. *Proc Nat Acad Sci.* 75:3283-3287, 1978.
56. Kemp MC, Wise KS, Edlund LE, **Acton RT**, Compans RW. Origin of the minor glycoproteins of murine leukemia viruses. *J Virol.* 28:84-94, 1978.

57. Wise KS, Cassell GH, **Acton RT**. Selective association of murine T-lymphoblastoid cell surface alloantigens with Mycoplasma hyorhinis. Proc Nat Acad Sci. USA 75:4479-4483, 1978.
58. **Acton RT**, Roseman JM. New vistas in the etiology, genetics, pathogenesis and natural history of juvenile-onset diabetes. J Med Assoc State AL. 48:25-39, 1978.
59. **Acton RT**, Wise KS, Barstad PA. Membrane antigens related to neoplasia and their possible escape significance. Handbook of Cancer Immunology. Vol. 2 (H Waters, Ed.), Garland STPM Press, New York, 161-171, 1978.
60. McClain LD, Tomana M, **Acton RT**. Purification and characterization of mouse brain Thy-1-2 differentiation alloantigens. Brain Research. 159:161-171, 1978.
61. **Acton RT**, Pfeiffer SE. Distribution of Thy-1 differentiation alloantigen in the rat nervous system and a cell line derived from a rat peripheral neurinoma. Develop Neuroscience 1: 110-117, 1978.
62. **Acton RT**, Barstad PA, Zwerner RD. Propagation and scaling up of suspension cultures. Methods in Enzymology Cell Culture, (WB Jacoby and IH Pastan, eds.) 58:211-221, Academic Press, New York, 1979.
63. Zwerner RD, Wise KS, **Acton RT**. Harvesting the products of cell growth. Methods of Enzymology Cell Culture (WB Jacoby IH Pastan, Eds) 58:221-229, Academic Press, NewYork, 1979.
64. Wise KS, Henley SL, **Acton RT**. Altered expression of T-lymphoid cell surface antigens associated with viral infection. ICN UCLA Symposia on Molecular and Cellular Biology, T and B Lymphocytes: Recognition and Function. (F Bach, B Bonavida, E Vitetta, CF Fox, eds.), Vol. XVI, 495-504, Academic Press, New York, 1979.
65. Wise KS, Asa PB, **Acton RT**. Interaction of murine T-cell surface antigens with Mycoplasma hyorhinis. Macrophages and Lymphocytes, Part B (MR Escobar and H Freeman, eds.) 65-80, Plenum Publishing Co., New York, 1980 Check Interaction of murine T-cell surface antigens with Mycoplasma hyorhinis. Adv Exp Med Biol. 121B:65-80, 1979.
66. Asa PB, **Acton RT**, Cassell GH, Wise KS. Identification and characterization of protein antigens of two Mycoplasma species. J Immunology 124:997-999, 1980.
67. Ades EW, Zwerner RK, **Acton RT**, Balch CM. Isolation and partial characterization of the human homologue of Thy-1. J Exp Med. 151:400-405, 1980.
68. Reitnauer PJ, Roseman JM, Barger BO, Murphy CC, **Acton RT**. HLA in juvenile diabetes. New Engl. J Med. 302:405-406, 1980.

69. **Acton RT**, Barger BO, Boshell BR, Kirk KA, Murphy CC, Reitnauer PJ, Roseman JM. Phenotypic markers of diabetes mellitus. *Autoimmune Aspects of Endocrine Disorders*. (A Pinchera, D Doniach, GF Fenzi, L Baschiere, eds.) 333-338 Academic Press, 1980.
70. **Acton RT**, Barger BO. The potential use of HLA to predict risk of malignant diseases and outcome of therapy. *Pediatric Oncology* (GB Humphrey, L Dehner, G Grindey, RT Acton, eds), Vol 1:47-77, Martinus Nijhoff Publishers, The Hague, 1981.
71. Reitnauer PJ, Roseman JM, Barger BO, Murphy CC, Kirk KA, **Acton RT**. HLA associations with insulin-dependent diabetes mellitus in a sample of the American black population. *Tissue Antigens* 17:286-293, 1981.
72. **Acton RT**, Barger BO, Boshell BR, Go RC, Murphy CC, Reitnauer PJ, Roseman JM. Epidemiology and genetics of insulin dependent diabetes mellitus in the white and black population from the southeastern United States. *Frontiers in Immunogenetics* (WH Hilderman, ed.) Elsevier-North Holland, New York 239-255, 1981.
73. Zwerner RK, Cox RM, Lynn JD, **Acton RT**. A five year perspective of the large scale growth of mammalian cells in suspension culture. *Biotech Bioeng.* 23:2717-2735, 1981.
74. Budowle B, Go RCP, **Acton RT**. Properdin factor B polymorphism in black Americans. *J Immunogenetics.* 8:519-521, 1981.
75. **Acton RT**, Barger BO. Guidelines for the use of genetic tests to establish paternity. *Birmingham Bar Assoc Bull.* (1):3-6, 1981.
76. Budowle B, Go RCP, **Acton RT**. Isoelectric focusing of hair proteins. *Electrophoresis* 81, (RC Allen P Arnaud, eds.) Walter de Gruyter, Berlin, 586-590, 1981.
77. Budowle B, **Acton RT**. A technique for the detection of variable electrophoretic patterns of hair proteins. *Electrophoresis* 2:333-334, 1981.
78. Budowle B, **Acton RT**, Barger BO. A method for dialysis of microsamples. *Anal Biochem.* 118:399-400, 1981.
79. Pittman WB, **Acton RT**, Barger BO, Bell DS, Go RCP, Murphy CC, Roseman JM. HLA-A -B and -DR associations with primary diabetes mellitus in those with onset after age 40. *Diabetes* 31:122-125, 1982.
80. **Acton RT**, Balch CM, Budowle B, Go RCP, Roseman JM, Soong SJ, Barger BO. Immunogenetics of Melanoma. *Melanoma antigens and antibodies*, (RA Reisfeld, S. Ferrone, eds.), Plenum Publishing Co., New York 1-21, 1982.
81. Budowle B, Barger BO, Balch CM, Go RCP, Roseman JM, **Acton RT**. Associations of properdin factor B with melanoma. *Cancer Genetics and Cytogenetics.* 5:247-251, 1982.

82. Alarcon GS, Koopman WJ, **Acton RT**, Barger BO. Seronegative rheumatoid arthritis: a distinct immunogenetic disease? *Arth Rheum.* 25:502-507, 1982.
83. Reitnauer PJ, Go RCP, **Acton RT**, Murphy CC, Budowle B, Barger BO, Roseman JM. Evidence for genetic admixture as a determinant in the occurrence of IDDM in U.S. blacks. *Diabetes.* 31:532-537, 1982.
84. Budowle B, Reitnauer PJ, Barger BO, Go RCP, Roseman JM, **Acton RT**. Properdin factor B in black IDDM patients. *Diabetologia.* 22:483-485, 1982.
85. Barger BO, **Acton RT**, Soong SJ, Roseman JM, Balch CM. Increase of HLA-DR4 in melanoma patients from Alabama. *Cancer Research* 42:4276-4279, 1982.
86. Budowle B, **Acton RT**, Barger BO, Blackstock R, Crist W, Go RCP, Humphrey GB, Ragab A, Roper M, Vietti T, Dearth J. Properdin factor B and acute lymphocytic leukemia (ALL). *Cancer* 50:2369-2371, 1982.
87. **Acton RT**, Balch CM, Barger BO, Budowle B, Go RCP, Soong SJ, Roseman JM. The occurrence of melanoma and its relationship with host, lifestyle and environmental factors. *Malignant Melanoma 1 (JJ Constanzi ed.)* Martinus Nijhoff Publishers. The Hague, 151-182, 1983.
88. Budowle B, Louv W, Barger BO, Go RCP, Roseman JM, **Acton RT**. Age at onset of insulin dependent diabetes mellitus associated with Bf1. *Immunogenetics* 17: 437-440, 1983.
89. Budowle B, Louv W, Barger BO, Go RCP, Roseman JM, **Acton RT**. Phenotypes of the fourth complement component (C4) in black Americans from the southeast United States. *J. Immunogenetics* 10:199-203.1983.
90. Budowle B, Go RCP, Roseman JM, Barger BO, **Acton RT**. C4 phenotypes in caucasians from the southeastern United States. *Electrophoresis* 82: (D. Stathakos ed.) Walter de Gruyter, Berlin, 715-723, 1983.
91. Murphy CC, **Acton RT**, Barger BO, Go RCP, Kirk KA, Reitnauer PJ, Roseman JM. Population genetic analyses of IDDM using HLA allele frequencies. *Clin. Genetics* 23: 405-414, 1983.
92. Alarcon GS, Koopman WJ, **Acton RT**, Barger BO. DR antigen distribution in blacks with rheumatoid arthritis. *J. Rheumatology* 10:579-583, 1983.
93. Alarcon GS, Koopman WJ, **Acton RT**, Barger B.O. CREG antigens differentially influence expression of extra articular manifestations in whites and blacks with rheumatoid arthritis. *Sem. Arth. Rheum.* 13:169-173, 1983.

94. Malone GE, Roseman JM, Crist WM, **Acton RT**. A review of evidence that the feline leukemia virus (FeLV) might be causative in childhood acute lymphocytic leukemia (ALL). *Pediatric Oncology Vol. 3*: Humphrey GB, Dehner LP, Grindey GB, Acton RT. (eds), Martinus Nijhoff Publishers, The Hague, 45-65, 1983.
95. Alarcon GS, Barger BO, **Acton RT**, Koopman WJ. Seronegative Rheumatoid Arthritis and B7-CREG: Disparate results. *Arthritis Rheum.* 26:1412-1413, 1983.
96. Murphy CC, Go RCP, **Acton RT**, Barger BO, Roseman JM. Genetic analysis of multiply affected families of insulin dependent diabetes melitus (IDDM) probands. *Hum. Hered.* 33: 344-356, 1983.
97. Budowle B, Roseman JM, Go RCP, Barger BO, **Acton RT**. The complement component C4 in black Americans with type 1 insulin-dependent diabetes mellitus. *Diabetologia* 26:166-168, 1984.
98. Neame PJ, **Acton RT**. A simple methodology for the routine production and partial Purification of human lymphoblastoid interferon. *Eukaryotic Cell Cultures: Basics and Applications*. Acton RT, Lynn JD. (eds) Plenum Press, New York, 269-279, 1984.
99. Henley SL, Wise KS, **Acton RT**. Productive murine leukemia virus (MuLV) infection of SL4 T-lymphoblastoid cells: Selective elevation of H-2 surface expression and possible association of Thy-1 antigen with viruses. *Eukaryotic Cell Cultures: Basics and applications*. Acton RT Lynn JD., eds. Plenum Press, New York, 365-381, 1984.
100. Go RCP, Olson G, **Acton RT**, Barger BO, Cutter G, Roseman JM, Copeland RB. Discussion: Association of factor B with ischemic heart disease (IHD). *Genetic Epidemiology of Coronary Heart Disease: Past, Present and Future*. Rao DC. (ed.) Alan R Liss Inc., New York 479-480, 1984.
101. Barger BO, **Acton RT**, Koopman WJ, Alarcon GS. DR antigens and gold toxicity in whites with rheumatoid arthritis. *Arthritis Rheum.* 27:601-605, 1984.
102. Alarcon GS, Koopman WJ, **Acton RT**, Barger BO. HLA-Bw35 and gold toxicity in rheumatoid arthritis. *Arthritis Rheum.* 28:236-237, 1985.
103. Budowle B, Dearth J, Bowman P, Crist W, Go RCP, Roseman JM, Barger BO, **Acton RT**. Genetic predisposition to acute lymphocytic leukemia in American blacks. *Cancer* 55:140-142, 1985.
104. **Acton RT**, Cox RM, Lynn JD, Zwerner RK. An approach to the large scale production of cells in suspension culture and the harvest of cell products. *Mammalian Cell Culture Technology*, Shikita M. Yamane J. (eds) Soft Science Publications, Tokyo, Japan, 19-33, 1985.
105. Alarcon GS, Gotuzzo E, Bocanegra TS, Castaneda MO, Calzo A, Carrillo C, Go RCP, **Acton RT**, Barger BO. Familial studies in human brucellosis. *Tissue Antigens* 26:77-79, 1985.



106. Alarcon GS, Phillips RM, Wasner CK, **Acton RT**, Barger BO. DR antigens in systemic sclerosis: Lack of clinical correlations. *Tissue Antigens* 26:156-158, 1985.
107. Bell DSH, **Acton RT**. Immunotherapy of insulin dependent diabetes. *Ala J Med Sci* 22: 311-314, 1985.
108. **Acton RT**, Hodge TW, McDaniel DO, Reveille JD, Napier-Littrell M, Barger BO. HLA restriction fragment length polymorphisms associated with insulin-dependent diabetes mellitus and the seronegative spondyloarthropathies. *Biosc Rep* 5:815-829, 1985.
109. **Acton RT**. Una Pericollosa Abbrangatura. *Sport and Medicina* 2:10-15, 1985.
110. **Acton RT**. I muscoli del sesso debole. *Sport and Medicina* 5:4-11, 1985.
111. Alarcon GS, Guyton JM, **Acton RT**, Barger BO, Koopman WJ. DR2 positivity and response to methotrexate in rheumatoid arthritis. *Arthritis Rheum.* 29:151, 1986.
112. McDaniel DO, Reveille JD, Barger BO, **Acton R**. Association of a restriction fragment length polymorphism (RFLP) with seronegative spondyloarthropathies (SNSA). *Biochemical Society Transactions* 14:85-86, 1986.
113. Hodge TW, Barger BO, Littrell MN, Bell DSH, Go RCP, **Acton RT**. DR beta restriction fragment length polymorphisms associated with insulin-dependent diabetes mellitus. *Biochemical Society Transactions* 14:86-88, 1986.
114. **Acton RT**. I Cromosomi nello sport. *Sport and Medicina* 3:10-13, 1986.
115. Cogen RT, Roseman JM, Al-Joburi W, Louv WC, **Acton RT**, Barger BO, Rasmussen RA. Host factors in juvenile periodontitis. *J. Dental Res* 65:394-399, 1986.
116. Alarcon GS, Barger BO, **Acton RT**, Koopman WJ. DR antigens and gold toxicity in American blacks with rheumatoid arthritis. *Rheumat. Intl.* 6:13-17. 1986.
117. **Acton RT**. Al caldo senza vischi. *Sport and Medicina* 3:27-30, 1986.
118. Guyton-Gispen J, Alarcon GS, Johnson JJ, **Acton RT**, Barger BO, Koopman WJ. Toxicity to methotrexate in rheumatoid arthritis. *J. Rheumatol.* 14:74-79, 1987.
119. Rabbani S, Galvin M, Louv W, McVay J, **Acton RT**, Barger B, Go RCP, Roseman JM. Risk factor surveys of the adult populations of the State of Alabama and Jefferson County. *Ala J Med Sci* 24:143-149, 1987.
120. Napier-Littrell M, **Acton RT**, McDaniel DO, Hodge TW, Barger BO. Association of restriction fragment length polymorphisms with MHC Class II phenotypes in white and black individuals. *Transplant Proc.* 19:826-832, 1987.

121. Alarcon GS, Billingsly LM, Clegg DO, Hardin JG, Klippel J, Luggen ME, Singer JZ, Svydlo L, Willkens RF, **Acton RT**, Barger BO, Koopman WJ. Lack of association between HLA-DR2 and response to methotrexate in rheumatoid arthritis. *Arthritis Rheum.* 30:218-220, 1987.
122. **Acton RT**. In divetta da Colorado Springs. *Sport and Medicina* 4:43-48, 1987.
123. Alarcon GS, Barger BO, Go RCP, **Acton RT**, Schrohenloher RE, Koopman WJ. Enhanced in vitro IgM rheumatoid factor synthesis in seropositive rheumatoid arthritis families. *Rheumatol Int* 7:71-75, 1987.
124. Hodge TW, Barger BO, **Acton RT**. DR $\beta$  Taq I restriction fragment length polymorphism (RFLP) associated with insulin dependent diabetes mellitus (IDDM). *Disease Markers* 5: 109-118, 1987.
125. Barger BO, **Acton RT**, Koopman WJ, Alarcon GS. Toxicity due to remission inducing drugs in RA. *J. Rheumatol.* 14:175-176, 1987.
126. McDaniel DO, Barger BO, Reveille JD, Alarcon GS, Koopman WJ, **Acton RT**. Analysis of restriction fragment length polymorphisms in rheumatic diseases. *Rheumatic Disease Clinics of North American*, Nathan J. Zvaifler (ed) 353-367, W.B. Saunders Co., Philadelphia. Pa. 1987.
127. Alarcon GS, McCarty G, Lanyon P, Phillips RM, **Acton RT**, Barber BO. Scleroderma, DR antigens, autoantibodies and clinical manifestations. *Clin. Exp. Rheum.* 5:317-322, 1987.
128. Bell DS. **Acton RT**. Barger BO. Vanichanan C. Clements RS. Futility of predicting onset of type I diabetes mellitus. *Diabetes Care* 10:788-789, 1987.
129. **Acton RT**. Evitiano Allarmismi inutili. *Scienza Veterinaria E. Biologia Animale* 6: 5-8, 1987.
130. Go RCP, Alarcon GS, **Acton RT**, Koopman WJ, Vittor VJ, Barger BO. Analysis of HLA linkage in white families with multiple cases of seropositive rheumatoid arthritis. *Arthritis Rheum.* 30:1115-1123, 1987.
131. McDaniel DO, **Acton RT**, Barger BO, Koopman WJ, Reveille JD. Association of a 9.2-kilobase Pvi II Class I major histocompatibility complex restriction fragment length polymorphism with ankylosing spondylitis. *Arthritis Rheum* 30:894-900, 1987.
132. Budowle B, Huddleston JF, Go RCP, Barger BO, **Acton RT**. Association of HLA-linked factor B with GDM in black women. *Am J Obstet Gynecol*, 159:805-806, 1988.
133. McDaniel, DO, **Acton RT**, Barger BO, Koopman WJ, Alarcon GS. Molecular genetic studies of rheumatoid arthritis. *Am J Med* 85: 23-25, 1988.
134. Reville JD, Barger BO, **Acton RT**, Koopman WJ, McDaniel DO. Restriction fragment length polymorphism analysis in ankylosing spondylitis. *Am J Med* 85:48-50, 1988.

135. Alarcon G, Morgan SL, **Acton RT**, Barger BO, Koopman WJ. Re: Methotrexate in the treatment of arthritis and connective tissue disease. *Cleve Clin J. Med.* 55:279, 1988.
136. **Acton RT**. Invisibili via importanti. *Sport and Medicina* 2:21-24, 1988.
137. Baur MP, Fimmers R, Fritsche C, Hummerlink M, Neugebauer M, **Acton RT**, Hodge T, Barbosa J, Bertrams J, Fehsel K, Kolb H, Rothe H, Boehm B, Cambon-Thomsen A, Avoustin P, Choppin H, Darnaud J, Massabie P, Ohayon E, de Preval C, Tauber JP, Thomsen M, Colle E, MacDonald MJ, Nevin D, Gottschall JL, Nepom GT, Robinson DM, Holbeck S, Palmer JP, Nerup J, Rotter JI, Vadheim C, Rittner C, Schneider P, Sheehy MJ, Cox NJ, Baker L, Spielman RS. Genetic analysis of IDDM: The GAW5 multiplex family dataset. *Genet Epidemiol* 6:15-20, 1989.
138. Cox NJ, Gogolin KJ, Horvath VJ, Barker DF, Wright E, Tran T, Skolnick MH, Boehm BO, Fehsel K, Bertrams J, Hodge TW, **Acton RT**, McGill J, Elbein SC, Permutt MA, De Preval C, Avoustin P, Cambon-Thomsen A, Robinson DM, Holbeck SL, Nepom GT, Schneider PM, Rittner C, Toyoda H, Rotter JI, Spielman R. Restriction fragment polymorphisms of the HLA-DR, HLA-DQ, and insulin gene regions in IDDM: The GAW5 data. *Genet Epidemiol* 6:21-26, 1989.
139. Reveille JD, Goodman RE, Barger BO, **Acton RT**. Familial polyarteritis nodosa: A serologic and immunogenetic analysis. *J Rheumatol.* 16:181-185, 1989.
140. McDaniel DO, Barger BO, **Acton RT**, Koopman WJ, Reveille JD. AS and a 9.2 kb Pvu II class I HLA DNA restriction fragment. *J Rheumatol.* 16:141-142, 1989.
141. Bamberg R, **Acton RT**, Goodson L, Go RCP, Struempfer B, Roseman JM. The effect of health risk assessment in conjunction with health promotion education on compliance with preventive behaviors. *J Allied Health.* 18:271-280, 1989.
142. Reveille JD, Schrohenloher RE, **Acton RT**, Barger BO. DNA analysis of HLA-DR and DQ genes in American blacks with systemic lupus erythematosus. *Arthritis Rheum* 32:1-9, 1989.
143. Paulsen G, Markussen G, **Acton RT**, Tiercy JM, Hammond MG, Fauchet R. RFLP standardization report for DR beta/Hind III. B. Dupont, (ed) *Immunology of HLA. Histocompatibility Testing 1987, Vol I.* 598-601, Springer-Verlag, New York, 1989.
144. **Acton RT**, Harman L. The use of DNA typing in cases of disputed paternity. *Promega Notes.* 22L 1-3, 1989.
145. McDaniel DO, Barger BO, **Acton RT**, Koopman WJ, Alarcon GS. Molecular analysis of HLA-D region genes in seropositive rheumatoid arthritis. *Tissue Antigens* 34:299-308, 1989.

146. **Acton RT**, Go RCP, Roseman JM. The use of family history of disease assessment (FHDA) instruments to target preventive measures. The Society of Prospective Medicine Proceedings of the 25<sup>th</sup> Annual Meeting, Indianapolis, Indiana. Risky Business 1989: Paying for Prevention. 88-104, 1989.
147. Roseman JM, Go RCP, **Acton RT**. The future of molecular biology in prospective medicine. The Society of Prospective Medicine. Proceedings of the 25<sup>th</sup> Annual Meeting. Risky Business 1989: Paying for Prevention. 105-118, 1989.
148. **Acton RT**, Hodge TW, Go RCP, Peiper SC, Harman L. A stratified approach to forensic identification by DNA analysis: A comparison of traditional genetic systems and restriction fragment length polymorphisms (RFLPs). Proceedings of the International Symposium on the Forensic Aspects of DNA Analysis, FBI, U.S. Department of Justice, U.S. Printing Office, Washington, D.C. 273-275, 1989.
149. **Acton RT**, Vanichanan CJ, Perkins L, Go RCP, Roseman JM, Barger BO, Bell DSH, Goldenberg RL, Winkler CL, Tucker JM, Hauth JC, Huddleston JF. Immunogenetic predictors of gestational diabetes in American blacks. Immunobiology of Normal and Diabetic Pregnancy. D. Andreani, G.D. Bompiani, U. di Mario, W.P. Faulk and A. Galluzzo (eds) John Wiley and Sons Ltd. Chichester, 12:207-220, 1990.
150. **Acton RT**, Harman L, Go RCP, Budowle B. Comparison of VNTR allele frequencies in white and black populations. Proceedings for the International Symposium on Human Identification. Promega, Madison, 5-20, 1990.
151. Azziz R, Wells G, **Acton RT**, Zacur HA. Pseudogene/functional gene ratio in late-onset 21-hydroxylase-deficient adrenal hyperplasia. Amer J Obstet Gynecol. 162:633-638, 1990.
152. Neggers YH, Cutter GR, **Acton RT**, Alvarez, JO, Bonner JL, Goldenberg RL, Go RCP, Roseman JM. A positive association between maternal serum zinc concentration and birth weight. Amer J Clin Nutrition. 51:678-684. 1990.
153. Bamberg R, **Acton RT**, Roseman JM, Go RCP, Barger BO, Vanichanan CJ, Copeland RB. The effect of genetic risk information on compliance with preventive health behaviors. Health Educ, 21:226-32, 1990.
154. **Acton RT**, Harman L, Go RCP. Comparison of HLA antigens and DNA Polymorphisms in parentage testing. Advances in Forensic Haemogenetics 3. Polesky HF. and Mayr WR. (eds) Springer-Verlag, Berlin 77-79, 1990.
155. Bamberg R, Copeland RB, Barger BO, Roseman JM, Go RCP, Vanichanan CJ. Brand JW, Jr, Moore PB, **Acton RT**. Genetic risk information as an impetus to health related behavioral change. The Society of Prospective Medicine Proceedings of the 24<sup>th</sup> Annual Meeting, Indianapolis, Indiana. Healthier People: New Trends in HRA and Health Promotion. 345-356, 1990.

156. **Acton RT**, Bamberg R, Go RCP, Roseman JM. Utilization of genetic and other laboratory test results to predict and reduce the risk of disease. The Society of Prospective Medicine Proceedings of the 24<sup>th</sup> Annual Meeting, Indianapolis, Indiana. Healthier people: new trends in HRA and Health Promotion. 261-276, 1990.
157. Roseman JM, Go RCP, **Acton RT**, Barger BO, Louv WC, Kramer JO, Jr, Bamberg R. A computerized system to assess risk of disease and mortality utilizing unusual genetic marker information. The Society of Prospective Medicine Proceedings of 23<sup>rd</sup> Annual Meeting Indianapolis, Indiana. Healthier People New Trends in HRA and Health Promotion. 205-211, 1990.
158. Roseman JM, Go RCP, Louv WC, Perkins L, Kramer J, Jr, Bamberg RA, Barger B, **Acton RT**. The Risk of Morbidity and Mortality Assessment (ROMMA). A health risk assessment utilizing genetic markers. The Society of Prospective Medicine Proceedings of the 24<sup>th</sup> Annual Meeting, Indianapolis, Indiana. Healthier People: New Trends in HRA and Health Promotion. 277-278, 1990.
159. Bell DSH, Barger BO, Go RCP, Goldenberg R, Perkins L, Vanichanan C, Roseman JM, **Acton RT**. Risk factors for gestational diabetes in black population. Diabetes Care. 13:1196-1201, 1990.
160. Demopoulos JT, Hodge TW, Wooten V, **Acton RT**. A novel DR2B1 allele in DR2-positive American blacks. Hum Immunol. 30:41-44, 1990.
161. Roseman J, Go RCP, **Acton RT**. The Future of Molecular Biology in Prospective Medicine. Proceedings of the twenty-sixth annual meeting of the Society of Prospective Medicine. 24-30. 1990.
162. Tilden AB, Zarcone D, Prasthofer EF, Lane VG, **Acton RT**, Grossi CE. X-linked codominant genes control all types of non-major histocompatibility complex-restricted cytotoxicity. Hum Immunol. 30:208-214, 1991.
163. Tucker JM, Winkler CL, Hauth JC, Goldenberg RL, **Acton RT**, Barger BO, Go RC, Bell DS, Perkins LL, Vanichanan, et al. Autoantibodies in black women with class A1, or class GB diabetes mellitus. Am J Perinatol. 8:103-105, 1991.
164. Winkler CL, Tucker JM, Hauth JC, Goldenberg RL, **Acton RT**, Barger BO, Go RC, Bell DS, Perkins LL, Vanichanan CJ, Roseman JM. Histocompatibility antigen subtypes in black women with class A1 or class GB diabetes mellitus. Am J Perinatol. 8:106-109, 1991.
165. Reveille JD, Anderson KL, Schrohenloher RE, **Acton RT**, Barger BO. Restriction fragment length polymorphism analysis of HLA-DR, DQ, DP and C4 alleles in Caucasians with systemic lupus erythematosus. J. Rheumatology. 18:14-18, 1991.

166. Azziz R, Wells G, Zacur HA, **Acton RT**. Abnormalities of 21-Hydroxylase gene ratio and adrenal steroidogenesis in hyperandrogenic women with an exaggerated 17-hydroxyprogesterone response to acute adrenal stimulation. *J Clin Endocrinol Metab.* 73: 1327-1331, 1991.
167. Dorman JS, **Acton RT**, and collaborating group. Familial insulin-dependent diabetes mellitus (IDDM) epidemiology: Standardization of data for the DIAMOND project. *Bull. WHO* 69:767-777, 1991.
168. Neggers, YH, Cutter GR, Alvarez JO, Goldenberg RL, **Acton RT**, Go RCP, Roseman JM. The relationship between maternal serum zinc levels at different times during pregnancy and birth weight. *Early Hum Dev.* 25:75-87, 1991.
169. Harman L, Go RCP, **Acton RT**. Comparison of VNTR allele frequencies in a sample of the black and white population of Alabama and the Southeast. *Proc. Second International Symposium on Human Identification, DNA Typing Laboratories*, 1991.
170. Roseman J, Go RC, Perkins LL, Barger BD, Bell DH, Goldenberg RL, DuBard MB, Huddleston JF, Sedlacek CM, **Acton RT**. Gestational Diabetes Mellitus Among African-American Women. *Diabetes/Metab Rev.* 7:93-104, 1991.
171. **Acton RT**, Go RCP, Roseman JM. Review of the evidence that immunogenetic factors are involved in the etiology of atherosclerosis. *Monogr. Hum. Genet. Lysis AJ. Rotter JI. Sparkes RS. (eds) Karger, Basel*, 14:253-271, 1992.
172. Kuwata S, Juji T, Sasaki T, Honda Y, Wong KH, Mervart HM, Haddad AP, **Acton RT**, Cross RA, Bing AJ, Mignot E, Grumet CFC. The first international collaborative study on narcolepsy. *Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Tsuji K. Yawa MA. Sasazuki T. (eds) Oxford University Press.* 1:730-734, 1992.
173. **Acton RT**, Bamberg R, Roseman JM. Integration of genetic information into preventive care. *Matzen RN. Lang RS. (eds) Clinical Preventive Medicine. St. Louis, Mosley* 765-783, 1993.
174. Roseman JM, **Acton RT**, Bamberg R. Health and genetic risk assessment instruments. *Matzen RN. Lang RS. (eds) Clinical Preventive Medicine. St. Louis, Mosley.* 784-798, 1993.
175. Bamberg R, **Acton RT**, Roseman JM. Health and genetic risk impact on preventive behaviors. *Matzen RN. Lang RS. (eds) Clinical Preventive Medicine. St. Louis, Mosley,* 799-810, 1993.
176. Wells G, **Acton RT**, Azziz R. Concordance of 21-hydroxylase gene ratio, HLA haplotyping and adrenal results in a family with late-onset adrenal hyperplasia. *J Reprod Med.* 38:615-620, 1993.

177. **Acton RT**, Bell DSH, Go RCP, Roseman JM, Tseng M-L, Louv W. The association of HLA phenotypes with hypertension in African Americans and Caucosoid Americans with type II diabetes, a population at risk for renal disease. *Transplant Proc.* 25:2400-2403, 1993.
178. **Acton RT**, Harman L, Go RCP, Tseng M-L, Bias W. Comparison of HLA phenotypes among African Americans from Alabama, Maryland and North Carolina. *Transplant Proc.* 25: 2404-2407, 1993.
179. **Acton RT**. Relationship of genes within the major histocompatibility complex to disease states. *Tissue Typing Reference Manual*. Tardif, GN. MacQueen JM. (eds) 1-15, SEOPF, Richmond, Virginia, 1993.
180. Tanizawa Y, Riggs AC, Chiu KC, Janssen RC, Bell DSH, Go RCP, Roseman JM, **Acton RT**, Permutt MA. Variability of the Pancreatic Islet beta cell/liver (GLUT2) glucose transporter gene in NIDDM patients. *Diabetologia.* 37:420-427, 1994.
181. Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez J, Macaluso M, **Acton RT**, Copeland RB, Cousins AL, Gore TB, Cornwell PE, Roseman, JM. Plasma homocysteine, folate and vitamin B12 concentrations and risk for early-onset coronary artery disease. *Am J. Clin Nutr.* 59:940-948, 1994.
182. Chiu KC, Go RCP, Aoki M, Riggs AC, Tanizawa Y, **Acton RT**, Bell DSH, Goldenberg RL, Roseman JM, Permutt MA. Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning. *Diabetologia.* 37:104-110, 1994.
183. **Acton RT**, Roseman JM, Bell DSH, Goldenberg RL, Tseng M-L, Vanichanan C, Harman LA, Go RCP. Genes within the major histocompatibility complex predict NIDDM in African-American women in Alabama. *Diabetes Care.* 17:1491-1494, 1994.
184. Reveille JD, Saurez-Almazor ME, Russell AS, Go RCP, Appleyard J, Barger BO, **Acton RT**, Koopman WJ, McDaniel DO. HLA in ankylosing spondylitis. Is HLA-B27 the only MHC gene involved in disease pathogenesis? *Semin Arthritis Rheum.* 23:295-309, 1994.
185. Roseman JM, Go RCP, **Acton RT**. Evidence for the "Genetic Admixture Hypothesis" that the increased incidence of IDDM among African Americans compared to Africans is due in large part to susceptibility gene(s) which entered through admixture with the European American gene pool. *Standardization of Epidemiologic Studies of Host Susceptibility*. Dorman JS (ed) Plenum Press, New York. 217-223, 1994.
186. Perry RT, Go RCP, Harrell LE, **Acton RT**. SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family. *Amer J. Med. Genet (Neuropsychiatric Genetics).* 60:12-18, 1995.
187. Bell DSH, **Acton RT**. Increased prevalence of mitral valve prolapse in IDDM. *Diabetes Care.* 19:672, 1996.

188. Barton JC, Harman L, Rivers C, **Acton RT**. Hemochromatosis: association of severity of iron overload with genetic markers. *Blood Cells Mol Dis.* 22:195-204, 1996.
189. Watson B, Jr, Bergman S, Myracle AL, Callen DF, **Acton RT**, Warnock DG. Genetic association of 11B-hydroxysteroid dehydrogenase type 2 flanking microsatellites with essential hypertension in African Americans. *Hypertension.* 28:478-480, 1996.
190. **Acton RT**. Molecular genetic testing for adult onset disorders: the evolving laboratory, physician, patient interface. *J Clin Lab Anal.* 11:23-37, 1997.
191. Barton JC, Shih W, Hirai J, Sawada-Hirai R, **Acton RT**, Harman L, Rivers C, Rothenburg BE. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. *Blood Cells Mol Dis.* 23:135-145, 1997.
192. **Acton RT**, Bell DSH, Collins J, Giger JN, Go RCP, Harrison R, McDonnald R, Rivers C, Roseman JM, Taylor HA Jr, Vanichanan C. Genes within and flanking the major histocompatibility region are risk factors for diabetes, insulin resistance, hypertension and microalbuminuria in African American Women. *Transplant Proc.* 29:3710-3712, 1997.
193. Barton JC, Rothenberg BE, Bertoli LF, **Acton RT**. Diagnosis of hemochromatosis in family members of probands: A comparison of phenotyping and HFE genotyping. *Genet Med.* 1: 89-93, 1999.
194. Barton JC, Sawada-Hirai R, Rothenberg BE, **Acton RT**. Two novel missense mutations of the *HFE* gene (I105T and G93R) and identification of the S65C Mutation in Alabama Hemochromatosis Probands. *Blood Cells Mol Dis.* 25:146-154, 1999.
195. **Acton RT**, Dasanayake AD, Harrison RA, Li Y, Roseman JM, Go RCP, Weiner H, Caufield PW. Associations of MHC genes with levels of caries-inducing organisms and caries severity in African-American women. *Hum Immunol.* 60:984-989, 1999.
196. Barton JC, **Acton RT**. Population screening for hemochromatosis: Has the time finally come? *Curr Gastroenterol Rep.* 2:1-9, 2000.
197. **Acton RT**, Harman L. Genetic counseling for hemochromatosis. In: *Hemochromatosis: Genetics, Pathophysiology, Diagnosis and treatment.* Barton JC, Edwards CO. (eds) Cambridge University Press, New York, 574-580, 2000.
198. Barton JC, Acton RT. Transferrin saturation phenotype and *HFE* genotype screening for hemochromatosis and primary iron overload: predictions from a model based on national racial, and ethnic group composition in central Alabama. *Genet Test.* 4:199-206, 2000.
199. **Acton RT**, Burst NM, Casebeer L, Ferguson SM, Green P, Laird BC, Leviton L. Knowledge, attitudes and behaviors of Alabama's primary care physicians regarding cancer genetics. *Acad Med.* 75:850-852, 2000.



200. Collins JS, Perry RT, Watson B, Jr, Harrell LE, **Acton RT**, Blacker D, Albert MS, Tanzi RE, Bassett SS, McInnis MG, Campbell RD, Go RCP. Association of a haplotype for tumor necrosis factor alpha in siblings with late-onset Alzheimer disease – The NIMH Alzheimer Disease Genetics Initiative. *Neuropsychiatric Genetics*. *Am J Med Genet*. 96:823-830, 2000.
201. Barton E, West P, Rivers C, Barton J, **Acton R**. Transferrin receptor 2 (TFR2) mutation Y250X in Alabama Caucasian and African American subjects with and without primary iron overload. *Blood Cells Mol Dis*. 27:279-284, 2001.
202. Barton JC, Wooten V, **Acton R**. Hemochromatosis and iron therapy of Restless Legs Syndrome. *Sleep Med*. 2:249-251, 2001.
203. **Acton RT**. The major histocompatibility complex, in *Clinical Immunology Principles and Practice*, Second Edition, Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroeder HW, Jr (eds) Mosby International Limited, London, Vol. 1, Ch. 6, 6.1 – 6.13, 2001.
204. Perry R, Collins JS, Harrell LE, **Acton RT**, Go RCP. Investigation of association of 13 polymorphisms in eight genes in Southeastern African-American Alzheimer's disease patients as compared to age-matched controls. *Am J Med Gen (Neuropsychiatric Genetics)*. 105:332-342, 2001.
205. Rivers C, Barton J, **Acton R**. A rapid PCR-SSP assay for the hemochromatosis-associated Tyr 250Stop mutation in the TFR2 gene. *Genet Test*. 5:131-134, 2001.
206. Barton J, **Acton R**. Inheritance of two common *HFE* mutations in African Americans: Cases with hemochromatosis phenotypes and estimates of hemochromatosis phenotype frequency. *Genet Med*. 3:294-300, 2001.
207. Barton, J, **Acton R**. Primary iron overload in African Americans: A review of clinical and genetic features. *J Natl Black Nurses Assoc*. 12:48-54, 2001.
208. **Acton RT**, Barton JC, Bell DSH, Go RCP, Roseman JM. *HFE* mutations in African American women with non-insulin-dependent mellitus. *Ethn Dis*. 11:578-584, 2001.
209. Go RCP, Desmond R, Roseman JM, Bell DSH, Vanichanan C, **Acton RT**. Prevalence and risk factors of microalbuminuria in a cohort of African-American women with gestational diabetes. *Diabetes Care*. 24:1764-1769, 2001.
210. Perry RT, Collins JS, Wiener H, **Acton R**, Go RCP. The role of TNF and its receptors in Alzheimer's disease. *Neurobiol Aging*. 22:873-883, 2001.
211. Barton JC, **Acton RT**, Prasthofer EF, Rivers CA. Hemochromatosis in a Lithuanian with *HFE* C282Y homozygosity and C282Y allele frequencies in the Baltic Sea region. *Eur J Haematol*. 67:263-264, 2001.

212. **Acton RT**, Barton JC. *HFE* Genotype frequencies in consecutive reference laboratory specimens: Comparisons among referral sources and association with initial diagnosis. *Genet Test*. 5:299-306, 2001.
213. Adams PC, Walker AP, **Acton RT**. A primer for predicting risk of disease in *HFE*-linked hemochromatosis. *Genet Test*. 5:311-316, 2001.
214. **Acton RT**, Barton JC, Casebeer L, Talley L. Survey of physician knowledge about hemochromatosis. *Genet Med*. 4:136-141, 2002.
215. Barton JC, Cheatwood SM, Key TJ, **Acton RT**, Hemochromatosis detection in a health screening program at an Alabama forest products mill. *J. Occup Environ Med*. 44:745-751, 2002.
216. Barton JC, Rao SV, Pereira NM, Gelbart T, Beutler E, Rivers CA, **Acton RT**. Juvenile hemochromatosis in the Southeastern United States: A report of seven cases in two kinships. *Blood Cells Mol Dis*. 29:104-115, 2002.
217. Barton JC, **Acton RT**. HLA-A and -B alleles and haplotypes in hemochromatosis probands with *HFE* C282Y homozygosity in central Alabama. *BMC Med Genet*. 3:9, 2002.
218. McLaren CE, Barton JC, Adams PC, Harris EL, **Acton RT**, Press N, Reboussin DM, McLaren GD, Sholinsky P, Walker AP, Gordeuk VR, Leiendecker-Foster C, Dawkins FW, Eckfeldt JH., Mellen BG, Speechley M, Thompson E., for the Hemochromatosis and Iron Overload Study Research Investigators. Hemochromatosis and iron overload screening (HEIRS) study design for an evaluation of 100,00 primary care-based adults. *Am J Med Sci*. 325:53-62, 2003.
219. Barton JC, Bertoli LF, **Acton RT**. HLA-A and -B alleles and haplotypes in 240 index patients with common variable immunodeficiency and selective IgG subclass deficiency in central Alabama. *BMC Med Genet*. 4:3 2003.
220. Barton JC, Bertoli LF, **Acton RT**. Common variable immunodeficiency and IgG subclass deficiency in central Alabama hemochromatosis probands homozygous for *HFE* C282Y. *Blood Cells Mol Dis*. 31:102-111, 2003.
221. Coghlan ME, Barton JC, Reymann MT, Ozbirn TW, **Acton RT**. *Vibrio vulnificus* infection in a hemodialysis patient receiving intravenous iron therapy. *Clin Infect Dis*. 37:e63-e67, 2003.
222. Barton JC, **Acton RT**, Rivers CA, Bertoli LF, Gelbart T, West C, Beutler E. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. *Blood Cells Mol Dis*. 31:310-319, 2003.
223. **Acton, RT**, Nabell LM. Assessing genetic risk of cancer. In: *Inherited Cancer Syndromes Current Clinical Management*, Ellis C.N., ed, Springer-Verlag, New York, 1-29, 2004.

224. Barton EH, Barton JC, Hollowell WW, **Acton RT**. Countries of ancestry reported by hemochromatosis probands and control subjects in central Alabama. *Ethn Dis.* 14:73-81, 2004.
225. Barton JC, Bertoli LF, **Acton RT**. *HFE* C282Y and H63D in adults with malignancies in a community medical oncology practice. *BMC Cancer.* 4:6, 2004.
226. Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet SC, Manley S, Culver JO, **Acton R**, Larsen-Haidle J, Correia LA, Bennett R, Pettersen B, Ferlita TD, Costalas JW, Hunt K, Donlon S, Skryznia C, Farrell C, Callif-Daley F, Vockley CW. Genetic cancer risk assessment and counseling: Recommendations of the National Society of Genetic Counselors. *J Genet Couns.* 13:83-114, 2004.
227. **Acton RT**, Barton EH, Hollowell WW, Dreibelbis AL, Go RCP, Barton JC. Ancestry reported by white adults with cutaneous melanoma and control subjects in central Alabama. *BMC Cancer.* 4:47, 2004.
228. **Acton RT**, Go RC-P, Roseman JM. Genetics and cardiovascular disease. *Ethn Dis.* 14: S2-8-16, 2004.
229. Barton JC, Rivers CA, Niyongere S, Bohannon SB. **Acton RT**. Allele frequencies of hemochromatosis gene (*HJV*) I222N and G320V missense mutations in white and African American subjects from the general Alabama population. *BMC Med Genet.* 5:29, 2004.
230. **Acton RT**, Barton JC. Hereditary Hemochromatosis. In: *Encyclopedia of Medical Genomics and Proteomics*, Fuchs J, Podda M eds, Marcel Dekker, Inc. New York. 605-611, 2004.
231. Barton JC, Wiener HW, **Acton RT**, Go RC-P. HLA haplotype A\*03-B\*07 in hemochromatosis probands with *HFE* C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. *Blood Cells Mol Dis.* 34:38-47, 2005.
232. Barton JC, **Acton RT**, Richardson AK, Brissie RM. Stainable hepatic iron in 341 African American adults at coroner/medical examiner autopsy. *BMC Clin Pathol.* 5:2, 2005.
233. Giger JN, Strickland OL, Weaver M, Taylor H, **Acton RT**. Genetic predictors of coronary heart disease risk factors in pre-menopausal African-American women. *Ethn Dis.* 15:221-232, 2005.
234. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, **Acton RT**, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Hemochromatosis and Iron Overload Screening (HEIRS) Study: Screening of a Population of Diverse Ethnic Background. *N Engl J Med.* 352:1769-1778, 2005.

235. Adams PC, Reboussin DM, Leiendecker-Foster C, Moses GC, McLaren GD, McLaren CE, Dawkins FW, Kasvosve I, **Acton RT**, Barton JC, Zaccaro D, Harris EL, Press R, Chang H, Eckfeldt JH. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Clin Chem.* 51:1048-1052, 2005.
236. Barton JC, **Acton RT**, Dawkins FW, Adams PC, Lovato L, Leiendecker-Foster C, McLaren CE, Reboussin DM, Speechley MR, Gordeuk VR, McLaren GD, Sholinsky P, Harris EL, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Initial Screening Transferrin Saturation Values, Serum Ferritin Concentrations, and *HFE* Genotypes in Whites and Blacks in the Hemochromatosis and Iron Overload Screening (HEIRS). *Genet Test.* 9:231-241, 2005.
237. Barton JC, Wiener HW, **Acton RT**, Go RC-P. Total blood lymphocyte counts in hemochromatosis probands with *HFE* C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles and haplotypes. *BMC Blood Disord.* 5:5, 2005.
238. Anderson RT, Press N, Tucker DC, Snively BM, Wenzel L, Ellis SD, Hall MA, Walker AP, Thomson EJ, Lewis-Jack O, **Acton RT**. Patient acceptability of genotypic testing for hemochromatosis in primary care. *Genet. Med.* 7:557-563, 2005.
239. Barton JC, **Acton RT**, Lovato L, Speechley MR, McLaren CE, Harris EL, Reboussin DM, Adams PC, Dawkins FW, Gordeuk VR, Walker AP, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Initial Screening Transferrin Saturation Values, Serum Ferritin Concentrations, and *HFE* Genotypes in Native Americans and Whites in the Hemochromatosis and Iron Overload Screening Study. *Clin Genet.* 69:48-57, 2006.
240. Lee P, Barton JC, Rao SV, **Acton RT**, Adler BK, Beutler E. Three kinships with *ALAS2* P520L (c. 1559 C → T) mutation, two in association with severe iron overload, and one with siderblastic anemia and severe iron overload. *Blood Cells Mol Dis.* 36:292-297, 2006.
241. Barton JC, Barton EH, **Acton RT**. Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with *HFE* C282Y homozygosity. *BMC Med Genet.* 7:22, 2006.
242. Tucker DC, **Acton RT**, Press N, Ruggiero A, Reiss JA, Walker AP, Wenzel L, Harrison B, Fadojutimi-Akinsiku M, Harrison H, Adams P, Crabb JA, Anderson R, Thomson E. Predictors of belief that genetic test information should be shared with family members. *Genet Test.* 10:50-59, 2006.
243. Adams PC, Passmore L, Chakrabarti S, Reboussin DM, **Acton RT**, Barton, JC, McLaren GD, Eckfeldt J H, Dawkins FW, Gordeuk VR, Harris, EL, Leiendecker-Foster C, Gossman, E, Sholinsky P, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Liver Diseases in the Hemochromatosis and Iron Overload Screening Study. *Clin Gastroenterol Hepatol.* 4:918-923, 2006.

244. McLaren CE, Li K-T, McLaren GD, Gordeuk VR, Snively BM, Reboussin DM, Barton JC, **Acton RT**, Dawkins FW, Harris EL, Eckfeldt JH, Moses GC, Adams PC. Mixture models of serum iron measures in population screening for hemochromatosis and iron overload. *Transl Res.* 148:196-206, 2006.
245. **Acton RT**, Barton JC, Snively BM, McLaren CE, Adams PC, Harris EL, Speechley MR, McLaren GD, Dawkins FW, Leidecker-Foster C, Holup JL, Balasubramanyam A, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Geographic and Racial/Ethnic Differences in *HFE* Mutation Frequencies in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Ethn Dis.* 16:815-821, 2006.
246. **Acton RT**, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, Bent TC, Vogt TM, Castro O. Relationships of serum ferritin, transferrin saturation, and *HFE* mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Diabetes Care.* 29:2084-2089, 2006.
247. Limdi NA, Beasley TM, Allison DB, Rivers CA, **Acton RT**. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. *Blood Cells Mol Dis.* 37:100-106, 2006.
248. Anderson RT, Wenzel L, Walker AP, Ruggiero A, **Acton RT**, Hall MA, Tucker DC, Thompson E, Harrison B, Howe E, III, Holup J, Leidecker-Foster C, Power T, Adams P. Impact of hemochromatosis screening in patients with indeterminate results: The Hemochromatosis and Iron Overload Screening Study. *Genet Med.* 8:681-687, 2006.
249. Rivers CA, Barton JC, Gordeuk VR, **Acton RT**, Speechley MR, Snively BM, Leidecker-Foster C, Press RD, Adams PC, McLaren GD, Dawkins FW, McLaren CE, Reboussin DM, for the Hemochromatosis and Iron Overload Screening Study. Association of Ferroportin Q248H Polymorphism with Elevated Levels of Serum Ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood Cells Mol Dis.* 38:247-252, 2007.
250. Power TE, Adams PC, Barton JC, **Acton RT**, Howe E, Palla S, Walker AP, Anderson R, Harrison B. Psychosocial Impact of Genetic Testing for Hemochromatosis in The HEIRS Study: A Comparison of Participants Recruited in Canada And in The United States. *Genet Test.* 11:55-64, 2007.
251. Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, **Acton RT**, McLaren GD, Vogt TM, Snively BM, Leidecker-Foster C, Holup JL, Passmore LV, Eckfeldt JH, Lin E, Adams PC. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. *Arch Intern Med.* 167:722- 726, 2007.

252. **Acton RT**, Snively BM, Barton JC, McLaren CE, Adams PC, Rich SS, Eckfeldt JH, Press RD, Sholinsky P, Leiendecker-Foster C, McLaren GD, Speechley MR, Harris EL, Dawkins FW, Gordeuk VR, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. A Genome-wide linkage scan for iron phenotype quantitative trait loci: the HEIRS Family Study. *Clin Genet.* 71:518-529, 2007.
253. Barton JC, **Acton RT**, Lee PL, West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-*HFE* iron overload in persons of sub-Saharan African descent. *Blood Cells Mol Dis.* 39:206-211, 2007.
254. Barton JC, **Acton RT**, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, Speechley MR, Reiss JA, Press RD, Dawkins FW, for the Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. *HFE* C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. *Genet Test.* 11:269-275, 2007.
255. McLaren CE, Barton JC, Gordeuk VR, Wu L, Adams PC, Reboussin DM, Speechley M, Chang H, **Acton RT**, Harris EL, Ruggiero AM, Castro O, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white *HFE* C282Y homozygotes in the hemochromatosis and iron overload screening study. *Am J Hematol.* 82:898-905, 2007.
256. Dawkin FW, Gordeuk VR, Snively BM, Lovato L, Barton JC, **Acton RT**, McLaren GD, Leiendecker-Foster C, McLaren CE, Adams PC, Speechley M, Harris EL, Jackson S, Thomson EJ. African Americans at risk for increased iron stores or liver disease: *Am J Med.* 120(8):734.e1-9, 2007.
257. **Acton RT**, Rivers CA, Watson B, Oh SJ. *DMPK*-associated myotonic dystrophy and CTG repeats in Alabama African Americans. *Clin Genet.* 72:448-453, 2007.
258. Hall MA, Barton JC, Adams PC, McLaren CE, Reiss JA, Castro O, Ruggiero A, **Acton RT**, Power TE, Bent TC. Genetic screening for iron overload: No evidence of discrimination at 1 year. *J Fam Pract.* 56:829-834, 2007.
259. Adams PC, Reboussin DM, Press RD, Barton JC, **Acton RT**, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Gordeuk VR, Lovato L, Eckfeldt JH. Biological variability of transferrin saturation and unsaturated iron-binding capacity. *Am J Med.* 120:999.e1-e7, 2007.
260. Walker AP, Tucker DC, Hall MA, Lohman K, Harrison H, Harrison BW, Reiss J, **Acton RT**, Adams PC, Diaz S, Holup J, Thomson E, Ellis SD, McLaren CE, for the Hemochromatosis and Iron Overload Study Research Investigators. Results communication and patient education after screening for possible hemochromatosis and iron overload: experience from the HEIRS Study of a large ethnically and linguistically diverse group. *Genet Med.* 9:778-791, 2007.

261. Limdi NA, Goldstein JA, Blaisdell JA, Beasley TM, Rivers CA, **Acton RT**. Influence of *CYP2C9* genotype on warfarin dose among African-American and European-Americans. *Per Med.* 4:157-169, 2007.
262. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, **Acton T**. Influence of *CYP2C9* and *VKORC1* on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. *Pharmacogenomics.* 9:511-526, 2008.
263. Barton JC, **Acton RT**, Leiendecker-Foster C, Lovato L, Adams PC, Eckfeldt JH, McLaren CE, Reiss JA, McLaren GD, Reboussin DM, Gordeuk VR, Speechley MR, Press RD, Dawkins FW, for the Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. *Am J Hematol.* 83:126-132, 2008.
264. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, **Acton RT**. Influence of *CYP2C9* and *VKORC1 1173C/T* genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. *Clin Pharmacol Ther.* 83:312-321, 2008.
265. McLaren CE., Gordeuk VR, Chen WP, Barton JC, **Acton RT**, Speechley M, Castro O, Adams PC, Snively BM, Harris EL, Reboussin DM, McLachlan GJ, Bean R, Hemochromatosis and iron Overload Screening Study Research Investigators. Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Transl Res,* 151:97-109, 2008.
266. Adams PC, Reboussin DM, Barton JC, **Acton RT**, Speechley M, Leiendecker-Foster C, Meenan R, Passmore L, McLaren CE, McLaren GD, Gordeuk V, Dawkins F, Eckfeldt JH. Serial serum ferritin measurements in untreated *HFE C282Y* homozygotes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Int J Lab Hematol,* 30:300-305, 2008.
267. Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, **Acton RT**, McLaren GD, McLaren CE, Harris EL, Reiss JA, Adams PC, Speechley M, Phatak PD, Sholinsky P, Eckfeldt JH, Chen W-P, Passmore L, Dawkins FW, Serum ferritin concentration and body iron stores in a multi-center, multi-ethnic primary care population. *Am J Hematol.* 83:618-626, 2008.
268. **Acton RT**, Barton JC, Passmore LV, Adams PC, McLaren GD, Leiendecker-Foster C, Speechley MR, Harris EL, Castro O, Reiss JA, Snively BM, Harrison BW, McLaren CE. Accuracy of Family History of Hemochromatosis or Iron Overload: The Hemochromatosis and Iron Overload Screening Study. *Clin Gastroenterol Hepatol.* 6:618-626, 2008.
269. Barton JC, Leiendecker-Foster C, Reboussin DM, Adams PC, **Acton RT**, Eckfeldt JH, Hemochromatosis and Iron Overload Screening Study Research Investigators. Thyroid-stimulating hormone and free thyroxine levels in persons with *HFE C282Y* homozygosity, a common hemochromatosis genotype: the HEIRS study. *Thyroid*18:831-838, 2008.

270. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, **Acton RT**, Liu N. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. *Pharmacogenomics*. 9:1445-1458, 2008.
271. Harrison HF, Harrison BW, Walker AP, Lohman K, Ellis SD, Hall MA, Reiss J, Adams PC, Holup J, **Acton RT**, Bent T, Rivers C, Fadojutimi-Akinsiku M. Screening for Hemochromatosis and Iron Overload: Satisfaction with Results Notification and Understanding of Mailed Results in Unaffected Participants of the HEIRS Study. *Genet Test*. 12:491-500, 2008.
272. McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, **Acton RT**, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, Eckfeldt JH. Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. *Can J Gastroenterol*. 22:923-930, 2008.
273. Adams PC, Pankow JS, Barton JC, **Acton RT**, Leiendecker-Foster C, McLaren GD, Speechley M, Eckfeldt JH. HFE C282Y homozygosity is associated with lower total and low-density lipoprotein cholesterol: The Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Circ Cardiovasc Genet*. 2:34-37, 2009.
274. Wang X, Leiendecker-Foster C, **Acton RT**, Barton JC, McLaren CE, McLaren G, Gordeuk VR, Eckfeldt JH. Heme carrier protein 1 (HCP1) genetic variants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study participants. *Blood Cells Mol Dis*. 42:150-154, 2009.
275. Barton JC, **Acton RT**. Hemochromatosis and *Vibrio vulnificus* wound infections. *J Clin Gastroenterol*. 43:890-893, 2009.
276. Barton JC, McGuire BM, **Acton RT**. HFE hemochromatosis and hepatic sarcoid. *Am J Med Sci*. 337:386-390, 2009.
277. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, **Acton RT**, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. *J Am Soc Nephrol*. 20:912-921, 2009.
278. Limdi NA, Wiener H, Goldstein JA, **Acton RT**, Beasley TM. Influence of *CYP2C9* and *VKORC1* on warfarin response during initiation of therapy. *Blood Cells Mol Dis*. 43:119-128, 2009.
279. Barton JC, **Acton RT**, Anderson LE, Alexander CB. A comparison between whites and blacks with severe, multi-organ iron overload identified in 16,152 autopsies. *Clin Gastroenterol Hepatol*. 7:781-785, 2009.
280. Adams PC, Barton JC, McLaren GD, **Acton RT**, Speechley M, McLaren CE, Reboussin DM, Leiendecker-Foster C, Harris EL, Snively BM, Vogt T, Sholinsky P, Thompson E, Dawkins FW, Gordeuk VR, Eckfeldt JH. Screening for Iron Overload: Lessons from the HEMochromatosis and Iron Overload Screening (HEIRS) Study. *Can J Gastroenterol*. 23:769-772, 2009.



281. Barton JC, Leiendecker-Foster C, Li H, DelRio-LaFreniere S, **Acton RT**, Eckfeldt JH, for the HEIRS Study. *HAMP* promoter mutation nc.-153C>T in 785 HEIRS Study participants. *Haematologica*. 94:1465, 2009.
282. Barton JC, LaFreniere SA, Leiendecker-Foster C, Li H, **Acton RT**, Press RD, Eckfeldt JH. *HFE*, *SLC40A1*, *HAMP*, *HJV*, *TFR2*, and *FTL* mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and *HFE* C282Y and H63D genotyping in 785 HEIRS study participants. *Am J Hematol*. 84:710-714, 2009.
283. Barton JC, Leiendecker-Foster C, Reboussin DM., Adams PC, **Acton RT**, Eckfeldt JH, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Relationships of serum free thyroxine and erythrocyte measures in euthyroid *HFE* C282Y homozygotes and control subjects in the HEIRS Study. *Int J Lab Hematol*. 32:282-287, 2010.
284. McLaren CE, Barton JC, Eckfeldt JH, McLaren GD, **Acton RT**, Adams PC, Henkin LF, Gordeuk VR, Vulpe CD, Harris EL, Harrison BW, Reiss JA, Snively BM. Heritability of serum iron measures in the hemochromatosis and iron overload screening (HEIRS) family Study. *Am J Hematol*. 85:101-105, 2010.
285. **Acton RT**, Barton JC, Leiendecker-Foster C, Zaun C, McLaren CE, Eckfeldt JH. Tumor necrosis factor-alpha promoter variants and iron phenotypes in 785 Hemochromatosis and Iron Overload Screening (HEIRS) Study participants. *Blood Cells Mol Dis*. 44:252-256, 2010.
286. Barton JC, Barton JC, **Acton RT**. Longer survival associated with HLA-A\*03, B\*14 among 212 hemochromatosis probands with *HFE* C282Y homozygosity and HLA-A and -B typing and haplotyping. *Eur J Haematol*. 85:439-470, 2010.
287. McLaren CE, Garner CP, Constantine CC, McLachlan S, Vulpe CD, Snively BM, Gordeuk VR, Nickerson DA., Cook JD, Leiendecker-Foster C, Beckman KB, Eckfeldt JH, Barcellos LF, Murray JA, Adams PC, **Acton RT**, Killeen AA, McLaren GD. Genome-Wide Association Study Identifies Genetic Loci Associated with Iron Deficiency. *PLoS One*. 6:e17390, 2011.
288. Barton JC, Barton JC, **Acton RT**, So J, Chan S, Adams PC. Increased risk of death from iron overload among 422 treated probands with *HFE* hemochromatosis and serum levels of ferritin greater than 1000 µg /L at diagnosis. *Clin Gastroenterol Hepatol*. 10:412-416, 2012.
289. McLaren CE, McLachlan S, Garner CP, Vulpe CD, Gordeuk VR, Eckfeldt JH, Adams PC, **Acton RT**, Murray JA, Leiendecker-Foster C, Snively BM, Barcellos LF, Cook JD, McLaren GD. Associations between Single Nucleotide Polymorphisms in Iron-related Genes and Iron Status in Multiethnic Populations. *PLoS One*;7(6) :e38339, 2012.
290. Gordeuk VR, Lovato L, Barton JC, Vitolins M, McLaren G, **Acton RT**, McLaren C, Harris EL, Speechley M, Eckfeldt JH, Diaz S, Sholinsky P, Adams P. Dietary iron intake and serum ferritin concentration in 213 homozygotes for the *HFE*<sup>C282Y</sup> hemochromatosis mutation. *Can J Gastroenterol* 26:345-349, 2012.

291. Murray JA, McLachlan S, Adams PC, Eckfeldt JH, Garner CP, Vulpe CD, Gordeuk VR, Brantner T, Leiendecker-Foster C, Killeen AA, **Acton RT**, Barcellos LF, Nickerson DA, Beckman KB, McLaren GD, McLaren CE. Association between celiac disease and iron deficiency in Caucasians, but not non-Caucasians. *Clin Gastroenterol Hepatol.* 11:808-814. Epub Feb 13, 2013.
292. Barton JC, Adams PC, **Acton RT**, Speechley M, McLaren CE, McLaren GD, Gordeuk VR, Eckfeldt JH. Proton Pump Inhibitors and Lower Serum Ferritin Levels in 171 HFE C282Y Homozygotes in the Hemochromatosis and Iron Overload Screening Study. *Vitam Miner* 2:2, 2013.
293. Costa M, Cruz E, Barton JC, Thorstensen K, Morais S, da Silva BM, Pinto JP, Vieira CP, Vieira J, **Acton RT**, Porto G. Effects of Highly Conserved Major Histocompatibility Complex (MHC) Extended Haplotypes on Iron and Low CD8(+) T Lymphocyte Phenotypes in HFE C282Y Homozygous Hemochromatosis Patients from Three Geographically Distant Areas. *PLoS One.* Nov 25; 8(11):e79990. 2013.
294. Barton JC, Barton JC, **Acton RT**. Diabetes in First-Degree Family Members: A Predictor of Type 2 Diabetes in 159 Nonscreening Alabama Hemochromatosis Proband with HFE C282Y Homozygosity. *Diabetes Care.* 37(1):259-66. 2014.
295. **Acton RT**, Barton JC, Barton JC. Serum ferritin, insulin resistance, and metabolic syndrome: clinical and laboratory associations in 769 non-Hispanic whites without diabetes mellitus in the HEIRS Study. *Metab Syndr Relat Disord.* Epub 2014 Nov 25. 13(2):57-63. 2015.
296. Barton JC, Edwards CQ, **Acton RT**. HFE (gene). [https://en.wikipedia.org/wiki/HFE\\_\(gene\)](https://en.wikipedia.org/wiki/HFE_(gene)) 2015.
297. Barton JC, Edwards CQ, **Acton RT**. *HFE*: Gene structure, function, mutations, and associated iron abnormalities. *Gene.* 574: 179-192, 2015.
298. Barton JC, Bertoli LF, Barton JC, **Acton RT**. Selective subnormal IgG3 in 121 adult index Patients with frequent or severe bacterial respiratory tract infections. *Cell Immunol.* 299: 50-57, 2016.
299. Barton JC, Barton JC, Adams PC, **Acton RT**. Risk factors for insulin resistance, metabolic syndrome, and diabetes in 248 HFE C282Y homozygotes identified by population screening in the HEIRS Study. *Metab Syndr Relat Disord.* 14:94-101, 2016.
300. Barton JC, Bertoli LF, Barton JC and **Acton RT**. Selective subnormal IgG1 in 54 adult index patients with frequent or severe bacterial respiratory tract infections. *J Immunol Res.* 2016:1405950. doi: 10.1155/2016/1405950. 2016.
301. Barton JC, Barton JC, Acton RT. White blood cells and subtypes in HFE p.C282Y and wild-type homozygotes in the Hemochromatosis and Iron Overload Screening Study. *Blood Cells Mol Dis.* 2017 Mar; 63:9-14. doi: 10.1016/j.bcmd.2016.11.008. Epub 2016 Nov 12.

302. Barton JC, Barton JC, Adams PC, Acton RT. Undiagnosed diabetes and impaired fasting glucose in *HFE* C282Y homozygotes and *HFE* wild-type controls in the HEIRS Study. *Diabetes Res Care*. 2016 Dec 26;4(1):e000278. doi: 10.1136/bmjdr-2016-000278. eCollection 2016.
303. Barton JC, Acton RT. Diabetes in *HFE* hemochromatosis. *J Diabetes Res*. 2017; 2017:9826930. doi: 10.1155/2017/9826930. Epub Feb 26, 2017.
304. Barton JC, Bertoli LF, Barton JC Acton RT. Fibromyalgia in 300 adult index patients with Primary immunodeficiency. *Clin Exp Rheumatol*. 2017 May-Jun;35 Suppl 105(3):68-73, Epub April 19, 2017.
305. Barton JC, Barton, JC, Acton RT. Insulin resistance and metabolic syndrome: clinical and laboratory associations in African Americans without diabetes in the HEIRS Study. *Metab Syndr Relat Disord*. Aug;16(6):267-273, Epub May 31, 2018.
306. Barton JC, Acton RT. Hepcidin, iron, and bacterial infection. *Vitam Horm*. Vol 110, Chapter 11, 223-242, Epub Feb 5, 2019.
307. Barton JC, Barton JC, Bertoli LF, Acton RT. HLA-A and -B type and haplotype frequencies in IgG subclass deficiency subgroups. *Archivum Immunologiae et Therapiae Experimentalis*. In press, 11/21/2019.
308. Barton JC, Wiener HH, Acton RT, Adams PC, Eckfeldt JH, Gordeuk VR, Harris EL, McLaren CE, Harrison H, McLaren GD, Reboussin DM. Prevalence of iron deficiency in 62,685 women of seven race/ethnicity groups: the HEIRS Study. *PLoS ONE*. Re-Submitted 02/14/2020.

**Abstracts:**

1. Sigel MM, Acton RT, Evans EE, Russell WJ, Wells TG, Painter B, Lucas AH. T2 bacteriophage dissemination and clearance in sharks. *J Reticuloendothelial Soc*. 4:432, 1967.
2. Acton RT, Bennett JC, Evans EE, Schrohenloher RE. Characterization of an oyster hemagglutinin. *Fed Proc*. 27:491, 1968.
3. Acton RT, Evans EE. Comparative immunology: T2 bacteriophage clearance and dissemination of the oyster. *Bacteriological Proc*. 68:66, 1968.
4. Acton RT, Evans EE, Bennett JC. Phylogenetic relationships of IgM antibodies. *Arthritis Rheum*. 12:654, 1969.
5. Acton RT, Evans EE, Bennett JC, Painter B. Immunoglobulins of the marine toad, *Bufo marinus*. *Fed Proc*. 28:752, 1969.

Frp p hqwbq#U4 ^##

6. Weinheimer PF, Evans EE, Acton RT, Painter B. Induced response of the lobster, *Panulirus argus*. Fed Proc. 28:752, 1969.
7. Acton RT, Evans EE, Weinheimer PF, Dupree HK, Bennett JC. Phylogeny of IgM antibodies. Fed Proc. 29:772, 1970.
8. Legler DW, Acton RT, Weinheimer PF. Hemagglutinin hemolysin and complement interrelationships in the gar. Fed Proc. 29:283, 1970.
9. Acton RT, Weinheimer PF. Carbohydrate compositions of immunoglobulins from several species of vertebrates. Fed Proc. 31:756, 1972.
10. Zwerner RK, Stanton RH, Weinheimer PF, Acton RT. Expression of Thy-1 and TL-a on murine leukemic lymphoblasts grown in various types of suspension culture apparatus. Fed Proc. 33:777, 1974.
11. Acton RT. Quantitation and tissue distribution of rat Thy-1 differentiation alloantigen. Fed Proc. 33:778, 1974.
12. Acton RT, Carl FG, Bridgers WF. The association of Thy-1 differentiation alloantigen with synaptic complexes isolated from mouse brain. Fed Proc. 34:553, 1975.
13. Runyan CC, Acton RT. Purification of plasma membranes from murine lymphoblastic cell lines expressing Thy-1 and TL alloantigen. Fed Proc. 34:553, 1975.
14. Zwerner RK, Acton RT. Growth properties and alloantigenic expression of murine lymphoblastic cell lines grown in suspension culture. Miami Winter Symposia. 9:1975.
15. Barstad PA, Weinheimer PF, Acton RT. Large scale production of H-2 antigens for structural determination. Fed Proc. 35:858, 1976.
16. Zwerner RK, Acton RT. The detergent extraction of Thy-1 from mouse thymocytes and lymphoblastoid cell lines. Fed Proc. 35:514, 1976.
17. McClain LD, Acton RT, Bridgers WF. Characterization of Thy-1 from isolated mouse brain synaptic membranes. American Society for Neurochem. 7:65, 1976.
18. Acton RT, McClain LD, Zwerner RK. A structural and functional analysis of mouse brain Thy-1. J Cell Biol. 70:263a, 1976.
19. McClain LD, Acton RT. The structural and functional characterization of Thy-1 isolated from mouse brain synaptic membranes Neuroscience Abstracts II:872, 1976.
20. Zwerner RK, Barstad PA, Acton RT. Purification and characterization of Thy-1.1 alloantigen from murine T-lymphoblastoid cell lines. Fed Proc. 36:702, 1977.

21. McClain LD, Acton RT. Purification and characterization of Thy-1 alloantigen from mouse brain. *Neuroscience Abstracts* III:318, 1977.
22. Wise KS, Acton RT. Alteration of murine leukemia virus (MuLV) cell surface antigens by infection with exogenous virus. *Proc Amer Assoc. Cancer Res.* 19:137, 1978.
23. Ades EW, Balch CM, Zwerner RK, Acton RT, Durant JR. Immunochemical characterization of two antigenic components on human normal and cultured T lymphocytes. *Proc Amer Assoc Cancer Res.* 19:137, 1978.
24. Zwerner RK, McClain LD, Barstad PA, Acton RT. Purification and structural relations of murine Thy-1. *J Supramolecular Structure.* 7, S2:134, 1978.
25. Acton RT McClain LD. Characterization of neuronal membrane differentiation alloantigen. *Amer Soc. For Neurochem.* 9:157, 1978.
26. Wise KS, Acton RT. Selective alternation of murine leukemia virus cell surface antigens by exogenous virus infection of T-lymphoblastoid cells. *J. Supramolecular Structure.* 8: S2, 1978.
27. Wise KS, Cassell GH, Acton RT. Interaction of murine T-cell surface antigens with *mycoplasma myorhinnis*. *Fed Proc.* 37:1851, 1978.
28. Asa PB, Acton RT, Cassell GH, Wise KS. Characterization of protein antigens from *mycoplasma pulmonis* and *mycoplasma hyorhinnis*. *Ann Meeting Amer Soc Microbiology.* 78:73, 1978.
29. Barstad PA, Zwerner RK, Tomana M, Acton RT. Purification and structural characterization of the murine T-cell differentiation alloantigen Thy-1. *Fed Proc.* 37: 1650, 1978.
30. Acton RT, Cassell GH, Wise KS. Interaction of murine T-cell surface antigens with *mycoplasma hyorhinnis*. *J Reticuloendothelial Society.* 23:25, 1978.
31. Wise KS, Acton RT. Characterization of biosynthetically labeled antigens of *Mycoplasma hyorhinnis*. *Ann Meeting Amer Soc Microbiol.* 79:163, 1970.
32. Reitnauer P, Murphy C, Barger B, Acton RT, Kirk K, Roseman JM. Analysis of epidemiological variables and HLA in black juvenile onset diabetics in Alabama. *Diabetes.* 28:432, 1979.
33. Murphy C, Reitnauer P, Barger B, Roseman JM, Kirk K, Acton RT. An analysis of a caucasoid juvenile onset diabetic population in Alabama. *Diabetes.* 28:433, 1979.
34. Wise KS, Henley SL, Acton RT. Association of murine lymphoid cell surface antigen expression with virus production, *J Supramolecular Structure.* Supplement 3:327, 1979.

35. Wise KS, Weinheimer PF, Acton RT. Multiple forms of H-2 antigens on a murine lymphoblastoid cell line. *Fed Proc.* 38:1979.
36. Henley SL, Acton RT, Wise KS. Association of productive murine leukemia virus (MuLV) infection with enhanced H-2 antigen expression on murine lymphoblastoid cells. *Fed Proc.* 38:927, 1979.
37. Barger B, Murphy K, Reitnauer P, Roseman JM, Boshell B, Acton RT. The association of Lewis blood groups with maturity-onset diabetes. *Fed Proc.* 38:1979.
38. Barger B, Murphy C, Reitnauer P, Boshell B, Roseman JM, Acton RT. Analysis of red blood cell markers in black and Caucasian diabetics. The Endocrine Society Meeting, Anaheim, CA June, 1979.
39. Reitnauer P, Murphy C, Barger B, Kirk K, Acton RT, Roseman JM. Genetic epidemiological analysis of a sample of the black juvenile-onset diabetic population in Alabama. *Amer Publ Hlth Assoc.* 107<sup>th</sup> meeting, 172, 1979.
40. Roseman JM, Murphy CC, Acton RT, Barger BO, Go RCP. Evidence from linkage analysis for a dominant mode of inheritance of susceptibility to juvenile-onset diabetes. *Clin Res.* 27:791A, 1979.
41. Acton RT, Barger BO, Murphy CC, Reitnauer PJ, Roseman JM. Phenotypic markers of diabetes mellitus. *Symp of Autoimmune Aspects of Endocrine Disorders*, 47, 1979.
42. Acton RT, Barger BO, Murphy CC, Roseman JM, Ingalls AL, Balch CM. Apparent association of HLA antigens with melanoma. *Proc Amer Assoc Cancer Res.* 21:49, 1980.
43. Reitnauer PJ, Acton RT, Barger BO, Budowle B, Murphy CC, Roseman JM, Go RCP. A population genetics study of insulin-dependent diabetes mellitus in young black Americans. *Amer J Hum Genet* 32:149A, 1980.
44. Murphy CC, Acton RT, Roseman JM, Reitnauer PJ, Barger BO. DRw analysis of black and white insulin-dependent diabetics and normal population samples. *Amer. Assoc. for Clin Histocomp Testing. Sixth Meeting*, A86, 1980.
45. Budowle B, Barger B, Go RCP, Murphy C, Reitnauer P, Roseman JM, Acton RT. Properdin factor B (Bf) phenotypes in blacks with insulin-dependent diabetes mellitus (IDDM). *Fed Proc.* 40:1113, 1981.
46. Barger BO, Budowle B, Go RCP, Acton RT. HLA-A-Bf and HLA-B-Bf black haplotype frequencies. *Amer Hist Test Seventh Meeting* A5, 1981.
47. Barger BO, Acton RT, Soong SJ, Roseman JM, Balch CM, Crist W. The association of HLA-DR4 with malignant melanoma in a Caucasian population from the Southern U.S. *Proc Ame. Assoc Cancer Res.* 22:71, 1981.

48. Budowle B, Go RCP, Acton RT. Isoelectric focusing of hair proteins. Electrophoresis, Charleston, S.C., 1981.
49. Budowle B, Balch CM, Barger BO, Go RCP, Roseman JM, Acton RT. Properdin factor B in malignant melanoma. Proc Amer Assoc Cancer Res. 22:71, 1981.
50. Pittman W, Acton RT, Barger B, Bell DS, Go RCP, Murphy C, Roseman JM. Genetics of late onset, lean, ketosis prone diabetes mellitus. Diabetes. 30:64A, 1981.
51. Alarcon GS, Barger BO, Koopman WJ, Acton RT. DR antigen distribution in blacks with rheumatoid arthritis. Arthritis Rheum. 24:S90, 1981.
52. Alarcon GS, Barger BO, Koopman WJ, Acton RT. Seronegative rheumatoid arthritis: a distinct immunogenetic disease. Arthritis Rheum. 24:S108, 1981.
53. Neame PJ, Parikh I, Acton RT. The potential of triazine dyes as absorbants for the purification of human lymphoblastoid interferon. 74<sup>th</sup> International Symposium on Affinity Chromatography and Related Techniques. June 22-26, 1981.
54. Go RCP, Murphy CC, Acton RT, Barger BO, Roseman JM. Pedigree analysis of 100 IDD families ascertained from the southeastern United States. Diabetologia. 21: 83, 1981.
55. Budowle B, Acton R, Barger B, Blackstock R, Crist W, Go RCP, Humphrey G, Ragab A, Vietta T, Dearth J. Properdin factor B (Bf) phenotypes predict risk of contracting acute lymphocytic leukemia. Blood. 58:136A, 1981.
56. Alarcon GS, Acton RT, Koopman WJ, Barger BO. DR antigens and gold toxicity in whites and blacks with seropositive rheumatoid arthritis. Preliminary report. Amer Rheum Assoc. 1981.
57. Go RCP, Murphy C, Acton RT, Roseman JM. Test of fit to dominant, recessive and intermediate major gene models with a sample of 100 IDDM families. Amer Soc Human Genetics 32<sup>nd</sup> Annual Meeting, 137A, 1981.
58. Budowle B, Acton RT, Allen RC. Structural proteins of hair as a forensic marker. Southern Association of Forensic Scientist, Birmingham, AL, September, 1981.
59. Alarcon GS, Acton RT, Koopman WJ, Barger BO. CREG antigen distribution in blacks and whites with rheumatoid arthritis. Arthritis Rheum. 25:S134, 1982.
60. Barger BO, Acton RT, Koopman WJ, Alarcon GS. DR antigens and gold toxicity in whites and blacks with rheumatoid arthritis (RA). Preliminary report. Arthritis Rheum. 25:S5, 1982.

61. Budowle B, Barger BO, Go RCP, Acton RT. C4 phenotype frequencies in an American Caucasian sample. Presented: Electrophoresis Soc Mtg. Athens, Greece, April, 1982.
62. Barger B, Balch C, Soong SJ, Roseman JM, Acton RT. HLA-B15 and HLA-DR3-Genetic markers for decreased risk in melanoma patients. Presented at AACHT meeting, April 1982.
63. Budowle B, Huddleston JF, Barger BO, Go RCP, Acton RT. Properdin factor B (Bf) as a predictor of non-obese gestational diabetes in black American women. *Diabetes*. 31(2): 65A, 1982.
64. Wells SJ, Roseman JM, Naftel D, Acton RT. Evaluation of physician awareness of the requirement to report juvenile onset diabetes (JOD). *Diabetes*. 31(2):103A, 1982.
65. Vittor VJ, Alarcon GS, Acton RT, Go RCP, Koopman WJ, Barger BO. Immunogenetics of rheumatoid arthritis: Comparison of simplex and multiple-affected families. *Amer J Hum Genet*. 157A, 1982.
66. Budowle B, Dearth J, Bowman P, Go RCP, Acton RT. Black children with certain factor B and C4 phenotypes are genetically predisposed to ALL. *Blood*. 60(5):121a, 1982.
67. McDaniel DO, Acton RT. A comparative analysis of the effects of K-562 cell membrane glycoproteins and glycolipids on human natural killer cells. 83<sup>rd</sup> Annual Meeting of the American Society of Microbiologists, 170, 1983.
68. Acton RT, Barger BO, Go RCP, Roseman JM, Soong SJ, Balch C. HLA-DR phenotypes predicts onset of melanoma in a subethnic group of Caucasians. *Proc Amer Assoc Cancer Res* 24:189, 1983.
69. McDaniel DO, Acton RT. A membrane glycoprotein of K-562 cell line as a probe for cell sorting of human natural killer cells. *Fed Proc*. 42:1379, 1983.
70. McDaniel DO, Barger BO, Alarcon GS, Acton RT. NK activity in rheumatoid arthritis and its association with HLA-DR antigen. *Clin Res*. 31:652A, 1983.
71. Vittor VJ, Alarcon GS, Koopman WJ, Acton RT, Go RCP, Barger BO. Segregation and family studies on seropositive rheumatoid arthritis. *Clin Res*. 31:455A, 1983.
72. Alarcon GS, Barger BO, Acton RT, Schrohenloher RE, Koopman WJ. Clinical and immunogenetic significance of IgA rheumatoid factor (Rf) in rheumatoid arthritis (RA). *Arthritis Rheum*. 26(4):S51, 1983.
73. McDaniel DO, Barger BO, Alarcon GS, Schrohenloher RE, Koopman WJ, Acton RT. The effect of rheumatoid factor (RF) on NK cell activity in DR4 positive rheumatoid arthritis. *Arthritis Rheum*. 26(4):S50, 1983.



74. Alarcon GS, Vittor VJ, Barger BO, Go RCP, Acton RT, Schrohenloher RE, Koopman WJ. IgM and IgG rheumatoid factor (RF) production in rheumatoid arthritis (RA) families. *Arthritis Rheum.* 26(4):S17, 1983.
75. Acton RT, Roseman JM, Go RCP, Barger BO, Budowle B. The association of complement C4 with type I diabetes mellitus in black Americans. *Diabetes.* 32:S 47A, 1983.
76. Barger BO, Dearth J, Crist W, Strandjord S, Humphrey B, Ragab A, Vietti T, Pullen J, Go RCP, Acton RT. A study of HLA associations in blacks and whites with leukemia. AACHT Ninth Annual Meeting 43, 1983.
77. Kahlon VS, Acton RT, Balch CM, Go RCP, Barger BO. The association of factor B with colon cancer. AACHT Ninth Annual Meeting 43, 1983.
78. Barger B, Dearth J, Crist W, Humphrey B, Ragab A, Pullen J, Go RCP, Vietti T, Acton RT. HLA association in black and white children with non-T, non-B ALL. *American Society Hematology*, 1983.
79. Acton RT, Olson G, Barger BO, Go RCP, Cutter G, Roseman JM, Copeland RB. Association of genes at the major histocompatibility complex with ischemic heart disease. *Clin Res.* 32:492A, 1984.
80. McDaniel DO, Acton RT. The effects of soluble membrane glycoproteins from K562 target cells on NK activity. *Fed Proc.* 43:1756, 1984.
81. Acton RT, McDaniel LS, McDaniel DO. Modification of NK cell activity by monoclonal antibodies to target cell glycoproteins. *Fed Proc.* 43:1758, 1984.
82. Bell D, Acton R, Barger B, Go RCP, Roseman JM, Louv W. The association of HLA phenotypes with hypertension in black Type II diabetic subjects. *Diabetes.* 33:S1, 120A, 1984.
82. Acton R, Olson G, Chandler J, Barger B, Go RCP, Cutter G, Roseman JM, Vanichanan C, Copeland R. Immunogenetic studies of early onset coronary heart disease in white males. *Amer J Hum Genet.* 36:128S, 1984.
84. Chandler J, Vanichanan C, Acton RT, Olson G, Barger B, Cutter G, Go RCP, Roseman JM, Simpson M, Copeland R. The association of auto-antibodies with coronary artery disease (CAH). *Clin Res.* 33:174A, 1985.
85. Alarcon GS, Guyton JM, Acton RT, Barger BO, Koopman WJ. Toxicity to methotrexate (MTX) in rheumatoid arthritis (RA). Clinical and HLA studies. *Arthritis Rheum.* 28(4):S36, 1985.

86. Alarcon GS, Guyton JM, Acton RT, Barger BO, Koopman WJ. Toxicity to methotrexate (MTX) in rheumatoid arthritis (RA). Clinical and HLA studies. Clin Res 33:785A, 1985.
87. Alarcon GS, Phillips RM, Wasner C, Acton RT, Barger BO. DR antigens in systemic sclerosis (SS). Clin Res. 33:785A, 1985.
88. Alarcon GS, Koopman WJ, Acton RT, Barger BO. HLA antigens in gold toxicity in blacks with rheumatoid arthritis (RA). Clin Res 33:785A, 1985.
89. Alarcon GS, Gotuzzo E, Bocanegra TS, Castaneda MO, Calvo A, Guerra J, Carrillo C, Hinojosa SA, Rolando I, Hernandez H, Go RCP, Acton RT, Barger BO, Espinoza LR. The arthritis of brucellosis (Br). Immunogenetic studies. Arthritis Rheum. 28(4):S97, 1985.
90. Alarcon GS, Ball GV, Blackburn WD, Vitek JJ, Barger BO, Acton RT. The value of CT scan in the evaluation of inflammatory back pain. Arthritis Rheum. 28(4):S22, 1985.
91. Barger B, Alarcon GS, Go RCP, Koopman WJ, Acton RT. Segregation and linkage studies on seropositive rheumatoid arthritis. Arthritis Rheum. 28(4):S47, 1985.
92. Vanichanan CJ, Huddleston JF, Barger BO, Go RCP, Louv W, Roseman JM, Acton RT. Immunogenetic factors of gestational diabetes mellitus. Diabetes. 34:S1, 269, 1985.
93. McDaniel O, Reveille J, Barger B, Acton RT. Association of a restriction fragment length polymorphism (RFLP) with seronegative spondyloarthropathies (SNSA). Biochemical Society Bulletin. 7:126, 1985.
94. Hodge T, Barger B, Littrell S, Bell D, Acton RT. Class II restriction fragment length polymorphism (RFLP) associated with insulin-dependent diabetes mellitus (IDDM). Biochemical Society Bulletin. 7:127, 1985.
95. McDaniel DO, Reveille JD, Barger BO, Acton RT. Molecular basis for the association of HLA-B27 phenotype with seronegative spondyloarthropathies (SNSA). Human Immunol 14:169, 1985.
96. Littrell MN, Acton RT, Hodge TW, Barger BO. Association of restriction fragment length polymorphisms (RFLPs) with HLA-DR serological types. Human Immunol. 14:194, 1985.
97. Hodge TW, Barger BO, Littrell MN, Bell DSH, Go RCP, Acton RT. The association of restriction fragment length polymorphisms (RFLPs) with insulin-dependent diabetes (IDDM). Am J Hum Genet 37:A140, 1985.
98. Alarcon GS, Barger BO, Go RCP, Acton RT, Schrohenloher RE, Koopman WJ. Familial rheumatoid arthritis: Clinical and in vitro follow up studies. Arthritis Rheum. 29:S44. 1986.

99. Reveille JD, Waldo FB, Barger BO, Acton RT. Differences in HLA antigens in SLE patients. *Arthritis Rheum.* 29:S44, 1986.
100. McDaniel DO, Barger BO, Koopman WJ, Acton RT, Alarcon GS. Analysis of class II MHC gene restriction fragment length polymorphisms (RFLPs) in RA. *Arthritis Rheum.* 29:S36, 1986.
101. Reveille JD, McDaniel DO, Koopman WJ, Barger BO, Acton RT. Restriction fragment length polymorphisms (RFLPs) in ankylosing spondylitis (AS): Association with 9.2 kb Pvu II fragment. *Arthritis Rheum* 29:S35, 1986.
102. Alarcon GS, McCarty G, Lanyon P, Phillips RM, Acton RT, Barger BO. Systemic sclerosis (SS), DR antigens, autoantibodies (AAB), and clinical manifestations. *Arthritis Rheum* 29:S40, 1986.
103. Alarcon GS, Barger BO, Acton RT, Koopman WJ. HLA antigens and gold salt (GS) toxicity in American blacks with rheumatoid arthritis. *Arthritis Rheum.* 29:S33, 1986.
104. Reveille JD, McDaniel DO, Barger BO, Koopman WJ, Acton RT. Restriction fragment length polymorphism (RFLP) in the seronegative spondyloarthropathies (SNSA). *Arthritis Rheum.* 29:S32, 1986.
105. Reveille JD, Barger BO, Acton RT. Demographic differences in the clinical presentation and immunogenetics of systemic lupus erythematosus (SLE). *Arthritis Rheum.* 29:S94, 1986.
106. McDaniel DO, Alarcon GS, Barger BO, Koopman WJ, Acton RT. The association of class II MHC restriction fragment length polymorphisms (RFLPs) with rheumatoid arthritis (RA). *Intl. Symp. On Monoclonals and DNA Probes in Diagnostic and Preventive Medicine, Florence, Italy, 101, 1986.*
107. Hodge TW, Napier-Littrell M, Barger BO, Acton RT. The relationship of HLA-DR types associated with disease states to MHC class II restriction fragment length polymorphisms (RFLP). *Intl. Symp. On Monoclonals and DNA Probes in Diagnostic and Preventive Medicine, Florence, Italy, 102, 1986.*
108. Barger BO, Shew HW, Hodge T, Acton R. Isolation of a DQ $\beta$  Homologous genomic clone that may recognize a subset of DQw3 in Southern blot analysis. *Amer Soc Histocompatibility and Immunogenetics 12<sup>th</sup> Annual Meeting, 68, 1986.*
109. Acton RT, McDaniel DO, Barger BO, Koopman WJ, Reveille JD. The usefulness of MHC class I restriction fragment length polymorphism (RFLP) in defining subsets of the seronegative spondyloarthropathies (SNSA). *Intl. Symp. On Monoclonals and DNA Probes in Diagnostic and Preventive Medicine, Florence, Italy, 103, 1986.*

110. Bell DSH, Barger BO, Go RCP, Holt C, Huddleston JF, Perkins LL, Roseman JM, Vanichanan CJ, Acton RT. Immunogenetic risk factors of gestational diabetes in a black population. *Diabetes*. 35:73A, 1986.
111. Alarcon GS, Billingsley LM, Clegg DO, Hardin JG, Klippel J, Luggen ME, Singer JZ, Sydlo L, Willkens RF, Acton RT, Barger BO, Koopman WJ. Response to methotrexate-(MTX) in rheumatoid arthritis (RA). *Immunogenetic Studies. Arthritis Rheum*. 29:S77, 1986.
112. McDaniel DO, Barger BO, Koopman WJ, Acton RT, Alarcon GS. Class II MHC restriction fragment length polymorphisms (RFLP) and HLA-DR4 in rheumatoid arthritis (RA). *Arthritis Rheum*. 29:S11, 1986.
113. Reveille JD, McDaniel DO, Barger BO, Koopman WJ, Acton RT. Association of a 9.2 kilobase Pvu II restriction fragment length polymorphism (RFLP) with the seronegative spondyloarthropathies (SNSA). *Clin Res* 34:621A, 1986.
114. Acton RT, Barger BO, Bell DSH, Perkins LL, Roseman JM, Vanichanan CJ, Huddleston JF. A longitudinal study of immunogenetic risk factors of gestational diabetes in a black population. *Symp. On Immunology of Diabetes*, Edmonton, Canada, 2:1, 1986.
115. Hodge TW, Napier-Littrell M, Barger BO, Acton RT. The association of MHC class II restriction fragment length polymorphism (RFLP) with insulin dependent diabetes. *Symp. Immunology of Diabetes*, Edmonton, Canada, 2:2, 1986.
116. Napier-Littrell M, McDaniel DO, Barger BO, Acton RT. Association of restriction fragment length polymorphisms (RFLP) with HLA serological types and a comparison of the white and black ethnic groups. *XI International Congress of Transplantation Society*, Helsinki, Finland, 1986.
117. Acton RT, Vanichanan CJ, Olson G, Chandler G, Barger BO, Go RCP, Roseman JM, Copeland R. Immunogenetic and AI/CIII polymorphisms are risk factors for early onset coronary heart disease. *7<sup>th</sup> Intl. Congress Human Genetics*, Berlin, West Germany. 750, 1986.
118. Harman L, Acton RT, Shoaf J, Perrin S, Barger BO. Preliminary report comparing common public determinants identified in pregnancy serum from American black and whites. *Amer. Soc. Histocompatibility Immunogenetics 12<sup>th</sup> Annual Meeting*, 78, 1986.
119. Acton RT, Alarcon G, Barger B, Koopman W, McDaniel D. Association of Class II MHC restriction fragment length polymorphisms (RFLP's) with seropositive rheumatoid arthritis. *Amer. Soc. Histocompatibility Immunogenetics 12<sup>th</sup> Annual Meeting*, 138, 1986.
120. McDaniel DO, Reveille JD, Barger BO, Alarcon GS, Koopman WJ, Acton RT. Molecular genetic analysis of MHC associated RFLP's with susceptibility to rheumatic disorders: 5<sup>th</sup> HLA and H-2 Cloning Workshop. 39, 1986.

121. McDaniel O, Alarcon G, Barger B, Koopman W, Acton R. Analysis of class II MHC restriction fragment length polymorphism (RFLP) in rheumatoid arthritis (RA). 7<sup>th</sup> Intl. Congress Human Genetics, Berlin, West Germany. 669, 1986.
122. Shew HW, Hodge T, Barger BO, Acton RT. Isolation of a clone from a DR3/3, DQw2/w2 genomic library that may recognize a subset of DQw2 in Southern blot analysis. 7<sup>th</sup> Intl. Congress Human Genetics. Berlin, West Germany. 669, 1986.
123. Reveille JD, McDaniel DO, Barger BO, Acton RT, Koopman WJ. Restriction fragment length polymorphism (RFLP) analysis in familial ankylosing spondylitis (AS): independent segregation of a 9.2 kb Pvu II RFLP from B27 haplotypes. *Arthritis Rheum.*30:34S. 1987.
124. Reveille JD, Phelps P, Acton RT, Koopman WJ, Barger BO, McDaniel DO. Restriction fragment length polymorphism (RFLP) analysis in the seronegative spondyloarthropathies (SNSA). Independent segregation of 9.21 kb Pvu II B7 cDNA RFLP and B27 haplotypes. *Arthritis Rheum.* 30:24S, 1987.
125. McDaniel DO, Acton RT, Barger BO, Koopman WJ, Alarcon GS. Increased relative Risk (RR) for rheumatoid arthritis (RA) in the presence of two different restriction fragment length polymorphisms (RFLP) and the HLA-DR4 phenotype. *Arthritis Rheum.*30:533, 1987.
126. Moore P, Acton RT, Barger BO, Brennen J, Chandler J. Immunologic and genetic risk indicators of early-onset coronary heart disease. *Amer Fed Clin Res.* 1987.
127. McDaniel DO, Acton RT, Barger BO, Koopman WJ, Reveille JD. Association of a 9.2-Kilobase Pvu II Class I major histocompatibility complex restriction fragment length polymorphisms with ankylosing spondylitis. *Arthritis Rheum.* 1987.
128. Saway PA, McDaniel DO, Acton RT, Barger BO, Alarcon GS, Koopman WJ. Bam HI restriction fragment length polymorphisms (RFLPs) analysis in American blacks (AB) with seropositive rheumatoid arthritis. *Arthritis Rheum.* 1987.
129. Acton RT, Perkins LL, Go RCP, Vanichanan CJ, Holt C, Barger BO, Bell DSH, Huddleston JF, Roseman JM. Immunogenetic risk factors of gestational diabetes mellitus (GDM) and subsequent diabetes in a black population. *Diabetes.* 36:130A, 1987.
130. Acton RT, Barger BO, Brennan J, Chandler J, Cousins J, Go RCP, Gore T, McDaniel D, Moore P, Olsen G, Simpson M, Vanichanan C, Wagenknecht L, Copeland R. Immunologic and genetic risk indicators of early-onset coronary heart diseases, *FASEB J.* 2: A1582, 1988.
131. Roseman JM, Go RCP, Perkins L, Barger B, Bell D, Goldenberg T, Huddleston J, Acton RT. Gestational diabetes mellitus (GDM) in blacks: A case control study. *Diabetes.*37:S1 52A, 1988.

132. Acton RT, Vanichanan CJ, Perkins L, Go RCP, Roseman JM, Barger BO, Bell DSH, Goldenberg R, Huddleston J. The association of autoantibody with gestational diabetes (GDM) in a sample of black women. *Diabetes*. 37:S1 208A, 1988.
133. McDaniel DO, Barger BO, Alarcon GS, Acton RT. Molecular analysis of HLA-D region genes in rheumatoid arthritis (RA). *Genome*. 30:S1 231, 1988.
134. Go R, Acton R, Roseman J, Barger B, Perkins L, Vanichanan C, Moore P, Brand J, Gore T, Brennan J, Cousins L, Copeland R. Immunogenetic risk factors for premature coronary artery disease in Southeastern USA population. *Genome*. 30:S1, 414, 1988.
135. Hodge TW, Demopolus JT, Barger BO, Bell DHS, Acton RT. Nucleotide sequence analysis of DQw3 genes in HLA-DR4 and DR5 American black insulin dependent diabetes. *Am J Hum Genet*. 433:A186, 1988.
136. Demopulos JT, Hodge TW, Barger BO, Acton RT. Nucleotide sequence analysis of the DRw53 gene in black and white individuals. *Hum Immunol*. 23:90, 1988.
137. Harman L, Acton R, Wintjen K, Perrin S, Hodge T, Barger B. Preliminary identification of molecular subtypes of HLA-DR9 in American blacks and whites. *Hum Immunol*. 23:104, 1988.
138. McDaniel DO, Acton RT, Hodge TW, Barger BO. The association of class I genes with seropositive rheumatoid arthritis. *Hum Immunol*. 23:122, 1988.
139. Tucker JM, Winkler CL, Hauth JC, Goldenberg RL, Acton RT, Barger BO, Go RCP, Bell DSH, Perkins LL, Roseman JM. Auto-antibodies in black women with A<sub>1</sub>/B gestational diabetes mellitus. *Soc Perinatal Obstetricians*. 1988.
140. Winkler CL, Tucker JM, Hauth JC, Goldenberg RL, Acton RT, Barger BO, Go RCP, Bell DSH, Perkins LL, Roseman JM. HLA associations in black women with A<sub>1</sub>/B gestational diabetes mellitus. *Soc Perinatal Obstetricians*, 1988.
141. Wells G, Azziz R, Acton RT, Zacur HA. Pseudogene/functional gene ratios in 21 hydroxylase deficient late onset congenital adrenal hyperplasia (locah). *Soc Gynecologic Investigation*. 1988.
142. Demopulos JT, Hodge TW, Acton RT. Nucleotide sequence variation in the HLA-DR2B2 gene. *Genetics*. 122:S34, 1989.
143. Acton RT, Go RCP, Roseman JM, Perkins LL, Vanichanan CJ, Sedlacek CM, Gore TB, Cousins AL, Brennan JA, Moore PB, Brand JW, Copeland RB. Use of self-administered family history of disease instruments to predict individuals at risk for cardiovascular diseases, hypertension and diabetes. *Am J Hum Genet*. 45:A275, 1989.

144. Go RCP, Acton RT, Roseman JM, Perkins L, Brand J, Sedlacek C, Vanichanan CJ, Cousins L, Gore R, Brennan J, Moore P, Copeland R. Apolipoprotein genetic variants and risk to coronary artery disease - are they independent of traditional risk factors? *Am J Hum Genet.* 45:A240, 1989.
145. Demopoulos JT, Hodge TW, Acton RT. Nucleotide sequencing of the HLA-DR2B2 gene in blacks reveals a new allele. *Hum Immunol.* 32A 4.3-08, 1989.
146. Acton RT, Go RCP, Roseman JM. Strategies for utilization of genetic and other laboratory tests results to predict and reduce the risk of disease. *Prevention* 89:22, 1989.
147. Bamberg R, Roseman JM, Go RCP, Vanichanan C, Brand J, Moore P, Barger BO, Acton RT, Copeland R. Genetic risk information and preventive behaviors. *Prevention* 89:23, 1989.
148. Acton RT, Harman L, Wintjen K, Jones C, Hodge TH, Go RCP. Comparison of HLA antigens and DNA polymorphisms in parentage testing. *International Symposium on the Forensic Aspects of DNA Analysis.* US Department of Justice FBI. 43, 1989.
149. Roseman JM, Go RCP, Perkins L, Barger BO, Bell DSH, Goldenberg R, Huddleston J, Acton RT. A multivariable analysis of the risk factors for onset of gestational diabetes mellitus (GDM) among black women. *Soc Epid Res.* 1989.
150. Go RCP, Perkins L, Vanichanan CJ, Sedlacek C, Copeland R, Moore P, Brand J, Acton RT. Relationships between coronary atherosclerosis standard risk factors, lipoproteins, and immunogenetics. *Soc Epid Res.* 1989.
151. Acton RT, Go RCP, Roseman JM. Family history of disease instruments designed to target preventive services. *Prevention.* 90, 1989.
152. Acton RT, Vanichanan CJ, Perkins L, Go RCP, Roseman JM, Bell DHS, Goldenberg R, Huddleston J. Association of immunogenetic factors with gestational diabetes mellitus (GDM) in blacks. *Diabetes.* 39:245A, 1990.
153. Acton RT, Vanichanan CJ, Perkins L, Go RCP, Roseman JM, Bell DHS, Goldenberg R, Huddleston J. Immunogenetics risk factors for gestational (GDM) and subsequent overt diabetes mellitus in American blacks. *Human Immunol, 16<sup>th</sup> Annual ASHI Meeting.* 67, 1990.
154. Acton RT. The evolving use of genetic information in prospective medicine. *26<sup>th</sup> Annual Meeting of the Society of Prospective Medicine* 14:3, 1990.
155. Azziz R, Wells R, Acton RT. Concordance of 21 Hydroxylase (21-OH) gene ratio, HLA typing and adrenal testing results in a family with late-onset adrenal hyperplasia (LOAH). *Soc Gynecologic Investigation.* 1990.

156. Acton RT, Go RCP, Roseman JM. Strategies for the utilization of genetic information to target preventive medicine. *Prevention* 91, 15, C500, 1991.
157. Acton RT, Rivers C, Robinson S, Go RCP, Goldenberg R, Perkins L, Sedlacek C, Vanichanan CJ, Bell DSH, Roseman JM. Lipids and their relationships with apolipoprotein alleles in black gestational diabetics. *Diabetes* 40:1, 1559, 1991.
158. Harman L, Acton R, Go RCP. Significant differences in VNTR allele frequencies within the black and white populations of Alabama and between the southeastern states. *Am J Hum Genet* 49:S 498, 1991.
159. Watson B, Go RCP, Mikhail I, Jones C, Woolley T, Wooten V, Acton R. Genetic epidemiology of narcolepsy. *Am J Hum Genet* 49:S 498, 1991.
160. Harman L, Go RCP, Acton R. Comparison of VNTR allele frequencies in a sample of the black and white population of Alabama and the southeast. *Proceedings of the 2<sup>nd</sup> International Symposium on Human Identification*. Promega Corporation, 319, 1991.
161. Watson B, Jones C, Mikhail I, Tseng ML, Go RCP, Woolley T, Wooten V, Harman L, Acton RT. Racial differences in the association of DR2/DQW1 with narcolepsy based on serological and DNA typing. *Hum Immunol* 32:S1:47, 1991.
162. Watson B, Jones C, Mikhail I, Go RCP, Woolley T, Wooten V, Acton RT. A study of the genetic epidemiology of narcolepsy utilizing HLA class II sequence specific oligonucleotides. *Southern Genetics Group Meeting*, 1991.
163. Perry R, Go RCP, Harrell L, McDaniel DO, Vanichanan CJ, Foster LJ, Acton RT. PCR-RFLP and SSCP analyses of the APP and PRNP gene in early-onset Alzheimer's disease patients. *Southern Genetics Group Meeting*, 1991.
164. Acton RT, Harman L, Trinidad AR, Go RCP. Comparisons of D2S44 and D4S139, Hae III VNTR allele frequencies in Southeastern U.S. and Puerto Rican Hispanics. *American Academy of Forensic Sciences, 44<sup>th</sup> Annual Meeting*, 1992.
165. Harman L, Go RCP, Acton RT. Comparisons of D2S44 and D4S139, Hae II VNTR allele frequencies in Southeastern blacks and whites. *American Academy of Forensic Sciences, 44<sup>th</sup> Annual Meeting*, 1992.
166. Acton RT, Bell DHS, Roseman JM, Go RCP, Goldenberg R, Tseng M-L, Mikhail I, Vanichanan CJ. Risk factors for the development of diabetes in blacks with gestational diabetes. *Diabetes* 41:SI, 628, 1992.
167. McGannon M, Watson B, Acton RT, Go RCP, Goldenberg R, Tseng ML, Mikhail I, Vanichanan CJ, Roseman JM. Apo B 3' flanking VNTR alleles and risk of diabetes and heart disease in black American women. *Southern Genetics Group Meeting*, 1992.



168. Watson B, Mikhail I, Qui Y, Tseng ML, Shettar S, Go RCP, Woley T, Popp S, Acton RT. Differences in the genetic significance of DR2 association among narcoleptics based on presence or absence of cataplexy in two Alabama populations. *Am J Hum Genet.* 51:A163, 1992.
169. Acton RT, Bell DHS, Go R, Roseman J, Tseng M-L, Louv W. The association of HLA phenotypes with hypertension in African Americans and Caucasian Americans with type II diabetes. A population risk for renal disease. Third International Samuel L. Kountz Symposium on Renal Disease and Transplantation in Blacks, p. 82, 1993.
170. Acton RT, Harman L, Go RCP, Tseng M-L, Bias W. Comparison of HLA phenotypes among African Americans from Alabama, Maryland and North Carolina. Third International Samuel L. Kountz Symposium on Renal Disease and Transplantation in Blacks. 83, 1993.
171. Acton RT, Roseman JM, Bell DHS, Goldenberg R, Tseng M-L, Vanichanan C, Harman L, Go RCP. Association of HLA-DR2 and DR2 and autoantibodies with gestational (GDM) and non-insulin dependent (NIDDM) diabetes in African American women (AA). *AUIMEI Suppl.* 43, 1993.
172. Lifton RP, Warnock D, Acton RT, Harman L, Lalouel JM. High prevalence of hypertensive-associated angiotensinogen variant T235 in African Americans. *Clin Res.* 41:260A, 1993.
173. Chiu KC, Aoki M, Tanizawa Y, Riggs A, Go RCP, Acton RT, Permutt MA. The glucokinase (GK) gene in gestational diabetes mellitus (GDM). *Diabetes.* 42:51, 212A, 1993.
174. Acton RT, Roseman JM, Bell DHS, Goldenberg R, Rivers C, Tseng M-L, Vanichannan CJ, Watson B, McGannon M, Go RCP. Insulin and apolipoprotein restriction fragment length polymorphisms (RFLP) associated with gestational (GDM), non-insulin dependent (NIDDM) diabetes and hyperlipidemia in African American (AA) women. *Diabetes.* 42:51, 210A, 1993.
175. Go RCP, Chiu KC, Permutt MA, Tanizawa Y, Aoki M, Riggs AC, Roseman JM, Acton RT. Defining the relationship of the glucokinase gene to the "diabetes associated phenotypes" in African American gestational diabetics. *Am J Hum Genet.* 53:806, 1993.
176. Acton RT, Roseman JM, Bell DSH, Goldenberg RL, Tseng M-L, Vanichanan CJ, Harman LA, Go RCP. Association of genes within the major histocompatibility complex with gestational and non-insulin dependent diabetes in African American Women. *Am J Hum Genet.* 53:771, 1993.
177. Perry RT, Go RCP, Harrell LA, Acton RT. NIMH genetic initiative: rare deletions in the human prion protein gene (PRNP): A possible susceptibility gene for Alzheimer's Disease in a single family. *Am J Hum Genet.* 53:1748, 1993.

178. Rivers CA, Shettar S, Go RCP, Tseng M-L, Matthews K, Vanichanan CJ, Wise M, Acton RT. Association of dinucleotide repeats within or flanking the MHC with narcolepsy. *Hum Immunol.* 40, S1:92, 1994.
179. Acton RT, Watson B, Rivers C, Go RCP, Tseng M-L, Vanichanan CJ, Harman LA, Wise M, Shettar S. Clarifying the association of genes within the major histocompatibility complex with narcolepsy. *Am J Hum Genet.* 55S:A145, 1994.
180. Watson B, Oh SJ, Robinson S, Acton RT. Myotonic dystrophy in an African American family. *Am J Hum Genet.* 55:A367, 1994.
181. Watson B, Shettar S, Go RCP, Vanichanan CJ, Qui Y, Tseng M-L, Acton RT. Racial differences in the association of HLA with narcolepsy. *American Psychiatry Sleep Society.* 1994.
182. Shettar S, Parikh S, Mountz JM, Acton R, Inampudi C. SPECT findings in narcolepsy. *Biological Psychiatry.* 35(9):684-684, 1994.
183. Acton RT, Watson B, Rivers C, Go RCP, Tseng M-L, Vanichanan CJ, Harman LA, Wise M, Shettar S. Clarifying the association of genes within the MHC with narcolepsy. *FASEB J.* 9:A240, 1995.
184. Rivers CA, Go RCP, Vanichanan CJ, Matthews K, Shettar S, Wise M, Nance M, Acton RT. Family study of narcolepsy and linkage to MHC markers, *American Psychiatry Sleep Society.* 1994.
185. Rivers CA, Shettar S, Go RCP, Tseng M-L, Matthews K, Vanichanan CJ, Wise M, Acton RT. Narcolepsy and cataplexy: dinucleotide associations within the MHC. *American Psychiatry Sleep Society.* 1994.
186. Acton R, Shettar S, Wise M, Vanichanan CJ, Tseng M-L, Cross K, Go RCP. A comparison of HLA-DR2 (DQB1-0602) associations with narcolepsy and diagnostic features in Caucasian Americans and African Americans. *American Psychiatry Sleep Society.* 1994.
187. Shettar S, Wise M, Vanichanan CJ, Tseng M-L, Singh KP, Go RCP, Matthews K, Acton RT. Clinical differences in cataplexy + and cataplexy - narcolepsy patients. *American Psychiatry Sleep Society.* 1994.
188. Shettar S, Wise M, Vanichanan CJ, Tseng M-L, Singh KP, Go RCP, Matthews K, Acton RT. Clinical differences in Caucasian and African American narcolepsy patients. *American Sleep Society.* 1994.
189. Acton RT, Rivers C, Shettar S, Wise M, Vanichanan C, Tseng M-L, Nance M, Go RCP. Genetic mapping of the narcolepsy predisposition gene within the major histocompatibility complex. *Hum Immunol.* 44:S1, 76, 1995.

190. Barton JC, Rivers C, Harman LA, Bertoli LP, Anderson JW, Acton RT. D6S105 (8) Frequencies in African American iron overload (AAIO) probands, Caucasian hemochromatosis (H) probands, and normal control subjects from Alabama. *Blood*. 88: 490a, 1996.
191. Acton RT, Bell DSH, Go RCP, Vanchannan CJ, Roseman JM. Genes within the MHC (Ch6p) and insulin VNTR (Ch1 lq) predict non-insulin dependent diabetes mellitus in high risk African American Women. *Am J Hum Genet*. 59:A 209, 1996.
192. Barton JC, Shih WWH, Sawada-Hirai, Bartoli LF, Acton RT, Rothenberg BE. Caucasian Hemochromatosis (H) mutation Cyc282Tyr in African American Iron Overload (AAIO), *J Invest Med*. 45:62a, 1997.
193. Rivers CA, Go RCP, Shettar S, Wise MS, Vanichanan T, Acton RT. Chromosome 6p microsatellites associated with narcolepsy in Caucasian and African Americans *Am J Hum Genet*. 59:A233, October 1996.
194. Perry RT, Collins JS, McDonald R, Sharrow N, Harrell LA, Acton RT, Go RCP. Evidence for Apo E4 association and E4E4/ACT-AA double homozygote interaction in population of Southeastern African-American AD patients: NIMH Genetics Initiative. *Am J Hum Genet*. 59:A277, October 1996.
195. Acton RT, Bell DSH, Collins J, Giger JN, Go RCP, Harrison R, McDonald R, Rivers C, Roseman JM, Taylor HA Jr, Vanichanan CJ. Genes within and flanking the major histocompatibility region are risk factors for diabetes, insulin resistance, hypertension and microalbuminuria in African American women. *Transplant Congresses. Samuel L. Kountz Symposium*. 37, 1997.
196. Hanson KA, Grennet HE, Aikens M, Vanichanan CJ, Acton RT, Go RCP, Booyse FM. Heterosis in the association of PAI-1, t-PA, u-PA and  $\beta$ -fibrinogen polymorphisms with premature coronary artery disease in African-Americans. *Am J Hum Genet*. 61S:A200, 1997.
197. Perry RT, Collins JS, McDonald R, Hanson KA, Sharrow N, Harrell LA, Acton RT, Go RCP. Effects of Apo E-4 allele and ACT-AA genotype upon the mean age of onset in a population of southeastern African-American AD patients: NIMH Genetics Initiative. *Amer J Hum Genet*. 61S:A208, 1997.
198. Barton JC, Shih WWH, Sawada-Hirai R, Acton RT, Harman, L, Rivers C, Rothenberg BE, Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes mapping within Ch6p are responsible for hemochromatosis. Presented at Iron Overload, Public Health, and Genetics, Centers for Disease Control and Prevention, Atlanta, GA, March 1997.

199. Barton JC, Shih WWH, Sawada-Hirai R, Acton RT, Harman L, Rivers C, Rothenberg BE: Caucasian hemochromatosis mutation Cys282Tyr in African American iron overload. Presented at Iron Overload, Public Health, and Genetics. Centers for Disease Control and Prevention, Atlanta, GA, March 1997.
200. Acton RT, Bell DSH, Bergman S, Go RCP, Harrison R, Roseman JM, Vanichanan CJ. Risk factors for microalbuminuria in African-American women with a history of gestational diabetes. Seventh Annual Nephrology Meetings. A-1, 1998.
201. Acton RT, Dasanayake AD, Harrison R, Li Y, Roseman JM, Go RCP, Wiener H, Caufield PW. Association of MHC genes with caries-inducing organisms and caries. *Hum Immunol.* 59:80, 1998.
202. Acton RT, Burst NM, Casebeer L, Ferguson SM, Green P, Laird BL, Leviton L. Assessing cancer genetics knowledge, attitudes and behaviors among Alabama primary care physicians. *Am J Hum Genet.* 63S:198A, 1998.
203. Go RCP, Collins JS, Watson B, Jr, Vanichanan CJ, Acton RT, Blacker D, Alford TJ, Tanzi R, McInnis MG, Bassett SS, Campbell D, Perry RT. Evidence for linkage to 6p21.3 in Alzheimer disease families containing APOE  $\epsilon$ 4/ $\epsilon$ 4 genotypes - The NIMH AD Study Group *Am J Hum Genet.* 63S:A290, 1998.
204. Barton J, Acton R, Edwards C, Rothenberg B, Bertoli L, Barton N, Alfred J, Anderson J, Shih W, Harman, L, Rivers C, Sawada-Hirai R. Iron Overload in African Americans: Phenotypic and Genotypic Characterization of Proband from Central Alabama. *Molecular Medicine and Hemochromatosis.* NIH, May 14-15, 1998.
205. Perry RT, Acton RT. A previously unreported nucleotide substitution in exon 8 of hMLH1 resulting in an Ile→Val change is detected in a family with history of colon cancer. *Cancer Center Research Retreat, Birmingham, Alabama, October 1998.*
206. Collins JS, Perry RT, Watson B, Jr, Harrell LE, Acton RT, Blacker D, Albert MS, Tamzo R, McInnis MG, Bassett SS, Go RCP. TNF polymorphisms in siblings with late onset Alzheimer disease – The NIMH Genetics Initiative AD Study Group. *Am J Hum Genet.* 65S:435, 1999.
207. Acton RT, Staples KA, Watson B, Rivers C, Harman L, Oh SJ. Myotonic dystrophy associated CTG repeats in African Americans compared to other populations. Southern Genetics Group, 22<sup>nd</sup> annual meeting, Panama City, FL 1999. *Proc Greenwood Genetic Center.* 19:145, 2000.
208. Harman L, Guay-Woodford L, Acton RT. Sensitivity and specificity of prenatal prediction of ARPKD in 50 families. Southern Genetics Group, 22<sup>nd</sup> annual meeting, Panama City, FL, 1999. *Proc Greenwood Genetics Center.* 19:149, 2000.

209. West PA, Rivers CA, Barton EH, Barton JC, Acton RT. Frequency of caucasian hemochromatosis-associated Tyr250Stop (Y250X) mutation in the non-classical Transferrin receptor gene *TFR2* in African Americans. *Blood*. 96:224a, 2000.
210. Barton, JC, Acton RT, Bertoli LF. Hemochromatosis and primary antibody deficiency: Occurance in the same individuals and frequency of *HFE* mutations in common variable Immunodeficiency (CVID) and IgG subclass deficiency (IgGSD). *Blood*. 96:46, 2000.
211. West P, Rivers C, Barton E, Barton J, Acton R. Frequency of caucasian hemochromatosis-associated Tyr250Stop (Y250X) mutation in the non-classical transferrin receptor gene *TFR2* in African Americans. *Blood*. 96:224a, 2000.
212. McLaren CE, Acton R, Adams P, Barton J, Dawkins FW, Eckfeldt JH, Harris EL, McLaren GE, Press N, Reboussin DM. Hemochromatosis and iron overload screening (HEIRS) study design. *Bioiron 2001 – World Congress on Iron Metabolism*. p 119, 2001.
213. Acton RT, Barton JC. *HFE* genotype frequencies in 526 reference laboratory specimens: Comparisons among referral sources and association with initial diagnosis. *Blood*. 98:864a, 2001.
214. Acton RT, Barton JC, Casebeer L, Talley L. A survey of 2,563 American physicians about knowledge of hemochromatosis. *Blood*. 98:427a, 2001.
215. Barton JC, Acton RT. HLA-A and –B types and haplotypes in hemochromatosis probands with *HFE* C282Y homozygosity in Alabama. *Blood*. 98:3b, 2001.
216. McLaren CE, Acton RT, Adams P, Barton JC, Dawkins FW, Eckfeldt JH, Harris EL, McLaren GD, Press N, Reboussin DM. Hemochromatosis and iron overload screening (HEIRS) study design. *Blood*. 98:3604, 2001.
217. McLaren CE, Acton R, Adams P, Barton JC, Dawkins FW, Eckfeldt JH, Harris E, McLaren GD, Press N, Reboussin DM. Hemochromatosis and iron overload screening (HEIRS) study design. Presented at the 8<sup>th</sup> Conference of the International Association for the Study of Disorders of Iron Metabolism and the 15<sup>th</sup> International Conference on Proteins of Iron Metabolism. Cairns, Australia, August 18-24, 2001.
218. Acton RT, Adams PC, Barton JC, Dawkins F, Eckfeldt JH, Gordeuk VR, Harris EL, McLaren CE, McLaren GE, Mellen BG, Reboussin DM, Sholinsky P, Speechley M, Thompson E. Hemochromatosis and iron overload screening study (HEIRS) – An interim analysis of 20,000 *HFE* genotypes by race/ethnicity and association with iron phenotype. *Genet Med*. 4:180, 2002.
219. Adams PC, Acton R, Barton JC, Dawkins F, Eckfeldt J, Gordeuk VR, Harris EL, McLaren CE, McLaren GD, Press N, Reboussin DM, Sholinsky P, Speechley M, Thomson E. Hemochromatosis and Iron Overload Screening Study (HEIRS). An interim analysis of 20,130 primary care persons. *Gastroenterology*. 122:A634, 2002.

220. Harris EL, Mellen BG, Adams PC, Acton R, Barton JC, McLaren GD, Dawkins F, Eckfeldt JH, Gordeuk VR, Lovato L, McLaren CE, Press N, Sholinsky P, Speechley M, Thomson E. Hemochromatosis and Iron Overload Screening (HEIRS) Study. Prevalence of elevated iron test levels by *HFE* genotype. *Am J Hum Genetics*.71S:83, 2002.
221. McLaren GD, Barton JC, Gordeuk VR, McLaren CE, Adams PC, Reboussin DM, Acton RT, Harris EL, Dawkins FW, Mellen BG, Sholinsky P, Speechley M, Eckfeldt JH. High *HFE* C282Y Homozygote Frequency in Caucasians but not in Hispanics, African Americans, or Asians: An Analysis of 50,290 Primary Care Patients in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood*. 100:447a, 2002.
222. Mellen BG, Kurt L. Lohman KL, Acton RT, Adams PC, Barton JC, Eckfeldt JH, Gordeuk VR, Harris EL, McLaren CE, Nancy Press N, Reboussin DM, Rivers CA, Sholinsky P, Speechley M, Thomson E. Replacement of Controls Through Constrained Random Sampling in a Case Control Design: The Hemochromatosis and Iron Overload Screening (HEIRS) Study. Presented at the 9<sup>th</sup> biennial CDC/ATSDR symposium on statistical methods: Study Design and Decision Making in Public Health, Atlanta, GA, January 28-29, 2003.
223. McLaren GD, Barton JC, Gordeuk VR, McLaren CE, Adams PC, Reboussin DM, Acton RT, Harris EL, Dawkins FW, Mellen BG, Sholinsky P, Speechley M, Eckfeldt JH. High *HFE* C282Y Homozygote Frequency in Caucasians but not in Hispanics, African Americans, or Asians: An Analysis of 50,290 Primary Care Patients in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Presented at the 6<sup>th</sup> International Symposium on Microbial Iron Transport, Storage and Metabolism and the 16<sup>th</sup> International Conference of the International BioIron Society, Bethesda, MD, May 4-9, 2003.
224. Dawkins FW, Mellen BG, Reboussin DM, McLaren CE, Sholinsky P, Acton RT, Adams PC, Barton JC, McLaren GD, Harris EL, Press N, Speechley M, Thompson E, Eckfeldt JH, Gordeuk VR. Comparison of screening serum ferritin concentrations and transferrin saturations in *HFE* wild-type African American and Caucasian HEIRS participants. Presented at the 6<sup>th</sup> International Symposium on Microbial Iron Transport, Storage and Metabolism and the 16<sup>th</sup> International Conference of the International BioIron Society, Bethesda, MD, May 4-9, 2003.
225. Adams P, Reboussin D, Acton R, Barton J, Gordeuk V, Dawkins F, McLaren C, McLaren G, Harris E, Press N, Speechley M, Thomson E, Eckfeldt J, Sholinsky P. Prevalence of self reported symptoms in the HEIRS Study: Differences by *HFE* genotype. Presented at the 6<sup>th</sup> International Symposium on Microbial Iron Transport, Storage and Metabolism and the 16<sup>th</sup> International Conference of the International BioIron Society, Bethesda, MD, May 4-9, 2003.
226. Harris EL, McLaren, CE, Adams PC, McLaren GD, Vogt TM, Mellen BG, Speechley M, Reboussin DM, Acton RT. Distribution of serum ferritin and transferrin saturation levels among Asians living in the U.S. and Canada: Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Am J Hum Genet*. 73:415, 2003.

227. Adams P, Reboussin D, Acton R, Barton J, Gordeuk V, Dawkins F, McLaren C, McLaren G, Harris E, Press N, Speechley M, Mellen B, Thomson E, Eckfeldt J, Sholinsky P. Prevalence of self-reported symptoms in the HEIRS study: Differences by HFE genotype. *Hepatology*. 38S:230A, 2003.
228. Barton JC, Bertoli LF, Griffith M., Downs N, Acton, RT. Survival, causes of death, and malignancies in hemochromatosis probands with *HFE* C282Y homozygosity diagnosed in medical care. *Blood*. 102:9b, 2003.
229. Barton JC, Barton JC, Bertoli LF, Acton RT. Comparison of clinical phenotype and HLA-A and -B types and haplotypes of hemochromatosis index patients with *HFE* genotypes C282Y/H63D or H63D/H63D. *Blood*. 102:10b, 2003.
230. Tucker DC, Crabb JA, Hicken B, Acton R, Press N, Reiss J, Wenzel L, Walker A, Power T, Holup J, Harris B, Dawkins R, Anderson R, Reboussin D. Hispanics differ from other ethnic groups in the HEIRS study in opinions about communicating genetic test information within families. *Soc Behavioral Med* 27:S142, 2004.
231. Adams PC, Zaccaro D, Reboussin D, Moses G, Eckfeldt J, Leiendecker-Foster C, McLaren C, McLaren G, Dawkins F, Gordeuk V, Acton R, Barton J, Harris E, Press R, Chang H. A comparison of the unsaturated iron binding capacity to transferrin saturation to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the HEIRS study. *Hepatology*. 40:232A, 2004.
232. Lee P L, Barton J C, Brandhagen D J, Niyongere, Bohannon S, Rivers CA., Acton RT, Beutler E. Hemojuvelin Mutations in Whites, Blacks and Asians with Primary Iron Overload and in Control Subjects. *Blood*. 104:3198, 2004.
233. Barton JC, Acton RT, Dawkins FW, Adams PC, Lovato L, Leiendecker-Foster C, McLaren CE, Reboussin DM, Speechley MR, Gordeuk VR, McLaren GD, Sholinsky P, Harris EL. Initial Screening Transferrin Saturations, Serum Ferritin Concentrations, and *HFE* Genotypes in Whites and Blacks in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood*, 104:3202, 2004.
234. Acton, RT, Snively BM, Barton JC, Adams PC, Eckfeldt JH, Harris EL, Dawkins FW, McLaren CE, Gordeuk VR, McLaren GD, Reboussin DM, Sholinsky P, Speechley MR, Holup J, Leiendecker-Foster C. Geographic and Race/Ethnicity Differences in *HFE* Mutation Frequencies and Iron Phenotypes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood*. 104:3211, 2004.
235. Anderson RT, Press N, Tucker D, Wenzel L, Snively B, Hall M, Ellis S, Walker A, Thomson E, Lewis-Jack O, Acton RT. A Randomized Trial Assessing Acceptability of DNA versus Blood Marker Testing to Detect Hemochromatosis In Primary Care Settings: The HEIRS Study. *Am J Hum Genet*. 1484, 2004.

236. Anderson RT, Press N, Tucker D, Wenzel L, Snively B, Hall M, Ellis S, Walker A, Thomson E, Lewis-Jack O, Acton RT. A randomized trial on acceptability of DNA versus blood marker testing to detect hemochromatosis in primary care settings: The HEIRS study. Presented at Healthcare Research and Quality Day, Wake Forest University School of Medicine, Winston-Salem, NC, December 2004.
237. Snively BM, Reboussin DM, McLaren C, Acton RT, Speechley M, Harris EL, Barton JC, Leiendecker Foster C, Gordeuk V. Inference under various multinomial distribution models for haplotypes under Hardy-Weinberg disequilibrium. Contributed paper at the Spring Meeting of the International Biometric Society, Eastern North American Region, Austin, TX, March 20-23, 2005.
238. Gordeuk VR, Dawkins FW, Barton JC, Acton RT, McLaren GD, McLaren CE, Harris EL, Reiss J, Adams PC, Speechley M, Phatak PD, Sholinsky P, Eckfeldt J, Reboussin DM. Possible causes of serum ferritin concentration elevations among 101,168 primary care patients based on clinical evaluation. *BioIron*. 20, 73, 2005.
239. McLaren CE, McLaren GD, Li K-T, Gordeuk VR, Snively BM, Reboussin DM, Barton JC, Acton RT, Dawkins FW, Harris EL, Eckfeldt JH, Moses GC, Adams PC. Mixture Models of Phenotypic Markers in Population Disease Screening for Hemochromatosis and Iron Overload. *BioIron*. 71, P131, 2005.
240. Adams PC, Reboussin DM, Leiendecker-Foster C, Moses GC, McLaren GD, McLaren CE, Dawkins FW, Kasvosve I, Acton RT, Barton JC, Zaccaro D, Harris EL, Press R, Chang H, Eckfeldt JH. A comparison of the UIBC to transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis. *BioIron*. 95, P227, 2005.
241. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RT, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P, for the Hemochromatosis and Iron Overload Screening Study Research Investigators Hemochromatosis and Iron Overload Screening (HEIRS) Study: Screening of a primary care population of 101,168 persons of diverse background. *BioIron*. 95, P228, 2005.
242. Barton JC, Acton RT, Dawkins FW, Adams PC, Lovato L, Leiendecker-Foster C, McLaren CE, Reboussin DM, Speechley MR, Gordeuk VR, McLaren GD, Sholinsky P, Harris EL, for the Hemochromatosis and Iron Overload Screening Study Research Investigators. Initial Transferrin Saturation, Serum Ferritin, and *HFE* Genotypes in Whites and Blacks in the HEIRS Study. *BioIron*. 96, P231, 2005.
243. Gordeuk VR, Dawkins FW, Barton JC, Acton RT, McLaren GD, McLaren CE, Harris EL, Reiss J, Adams PC, Speechley M, Phatak PD, Sholinsky P, Eckfeldt JH, Reboussin DM. Possible causes of serum ferritin concentration elevations among 101,168 primary care patients based on clinical evaluation. *BioIron*. 2005.



244. Harris EL, Acton RT, Snively BM, Barton JC, Leiendecker-Foster C, McLaren CE, Adams PC, Speechley M, Bent TC. Using family history of hemochromatosis or iron overload to aid targeted screening in a multiethnic, primary-care population: The Hemochromatosis and Iron Overload Screening (HEIRS) Study. Poster #1194 presented at the annual meeting of The American Society of Human Genetics, October 25-29, 2005, Salt Lake City, Utah. Available from <http://www.ashg.org/genetics/ashg05s/>
245. Hall M, Snively B, Barton J, Castro O, Ruggiero A, Reiss J, McLaren C, Acton R, Adams P, Fadojutimi-Akinsiku M. A Prospective Study of Reported Genetic Discrimination after Screening for Hemochromatosis and Iron Overload. Poster #1220 presented at the annual meeting of The American Society of Human Genetics, October 25-29 2005, Salt Lake City, Utah. Available from <http://www.ashg.org/genetics/ashg05s/>
246. Barton JC, Acton RT, Lovato L, Speechley MR, McLaren CE, Harris EL, Reboussin DM, Adams PC, Dawkins FW, Gordeuk VR, Walker AP. Initial screening transferring saturation values, serum ferritin concentrations, and *HFE* genotypes in Native Americans and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood*. 106:3712, 2005.
247. Acton RT, Barton RT, Passmore L, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, Bent TC, Vogt T, Castro O. Relationships of serum ferritin, transferring saturation, and *HFE* mutations and self-reported diabetes mellitus in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. *Blood*. 106:3713, 2005.
248. Lee PL, Barton, Acton RT, Rao SV, Adler BK, Beutler E. Three kinships with *ALAS2* P520L mutations, two in association with severe iron overload, and one with siderblastic anemia and severe iron overload. *Blood*. 106:3723, 2005.
249. Adams PC, Passmore L, Chakrabarti S, Reboussin DM, Acton RT, Barton J, McLaren G, Eckfeldt J, Dawkins FW, Gordeuk V, Harris EL, Leiendecker-Foster C, Gossman E, Sholinsky P. Liver diseases in participants with elevated transferrin saturation and serum ferritin in the Hemochromatosis and Iron Overload Screening Study (HEIRS). Presented at the World Congress of Gastroenterology meeting in Montreal, Quebec, Canada, September 10 – 14, 2005. (On-line citation, <http://www.pulsus.com/WCOG/abs/LB.081.htm>).
250. McLaren CE, Gordeuk VR, Snively BM, Chen W-P, Harris EL, Adams PC, Barton JC, Castro O, Speechley M, Acton RT, Reboussin DM. Mixture models of bivariate distributions for Biochemical markers of iron status: The Hemochromatosis and Iron Overload (HEIRS) Screening Study. Presented at the 2006 WNAR/IMS Western Regional Meeting, Flagstaff, AZ, June 27-30, 2006.
251. Acton R, Snively B, Barton J, McLaren C, Adams P, Rich S, Eckfeldt J, Press R, Sholinsky P, Leiendecker-Foster C, McLaren G, Speechley M, Harris E, Dawkins F, Gordeuk V. A genome-wide scan suggests a region on chromosome 16p is a determinant of serum ferritin after adjusting for *HFE*: The HEIRS Family Study. Poster #1482/B presented at the annual meeting of The American Society of Human Genetics, October 9-13 2005, New Orleans, LA. Available from <http://www.ashg.org/genetics/ashg05s/>

252. DelRio-LaFreniere S, Li H, Leiendecker-Foster C, Zaun C, Thompson N, Wang X, Press R, Acton R, Eckfeldt J. Multiplex Analysis Using Denaturing High-Performance Liquid Chromatography (dHPLC) to Screen for Gene Variants Associated with Iron Overload. *J Mol Diagn.* 8:667, 2006.
253. Adams P, Reboussin D, McLaren CE, Acton RT, Barton JC, Gordeuk VR, Dawkins FW, McLaren GD, Harris EL, Press R, Moses GC<sup>1</sup>, Lovato L, Chang H, Leiendecker-Foster C, Eckfeldt J. Do the biological variability of transferrin saturation and unsaturated iron binding capacity limit their utility as screening tests for *HFE* C282Y linked hemochromatosis? *Hepatology.* 44:432A, 2006.
254. McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley M, Sholinsky P, Dawkins FW, Snively BM, Vogt T, Eckfeldt JH. Symptoms and signs of Hemochromatosis in *HFE* C282Y homozygotes identified by screening in primary care. *Blood.* 108:1545, 2006.
255. Limdi NA, McGwin G, Blaisdell J, Goldstein JA, Baird MF, Rivers CA, Acton RT. The pharmacogenetic optimization of anticoagulation therapy (POAT): Influence of CYP2C9 genotype on risk of major hemorrhagic complications in patients on warfarin. *Pharmacogenomics.* Cold Springs Harbor, 11/2006.
256. Adams PC, Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Passmore LV, Eckfeldt JH, Lin E. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. *Asian Pacific Liver Meeting Kyoto, Japan, 2007.*
257. Adams P.C, Reboussin DM, Barton JC, Gordeuk VR, Leiendecker-Foster C, McLaren CE, Acton RT, Eckfeldt JH, Dawkins FW, Speechley MR, Meenan RT, McLaren GD, Harris EL, Snively BM. Quantitative phlebotomy results from an ethnically and racially diverse primary care sample. *International BioIron Society Meeting, Kyoto, Japan April 1-6, 2007.*
258. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, Leiendecker-Foster C, McLaren GD, Dawkins FW, Gordeuk VR, Lovato L, Eckfeldt JH. A comparison of fasting and non-fasting transferrin saturation in the detection of C282Y homozygotes in the HEIRS Study. *International BioIron Society Meeting, Kyoto, Japan April 1-6, 2007.*
259. McLaren CE, Harris EL, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, Vogt TM, Snively BM, Leiendecker-Foster C, Holup JL, Passmore LV, Eckfeldt JH, Lin E, Adams PC. Serum ferritin and transferrin saturation in Asians and Pacific Islanders living in the U.S. and Canada: The Hemochromatosis and Iron Overload Screening (HEIRS) Study. *International BioIron Society Meeting, Kyoto, Japan April 1-6, 2007.*
260. McLaren GD, Gordeuk VR, Reboussin DM, Barton JC, Acton RT. McLaren CE, Harris EL, Reiss JA, Adams PC, Speechley M, Phatak PD, Sholinsky P, Eckfeldt JH, Passmore L, Dawkins FW. Serum ferritin concentration and body iron stores among 101,168 primary care participants. *International BioIron Society Meeting, Kyoto, Japan April 1-6, 2007.*

261. McLaren CE, Gordeuk VR, Chen W-P, Barton JC, Acton RT, Speechley M, Castro O, Adams PC, Snively BM, Harris EL, Reboussin DM, McLachlan GJ, Bean R, McLaren GD. Subpopulations with Iron Deficiency, Liver Disease, or *HFE* Mutations Revealed by Statistical Mixture Modeling of Transferrin Saturation and Serum Ferritin Concentration in Asians, African Americans, Hispanics, and Whites. *Blood*. 110:2672, 2007.
262. Limdi NA, Acton RT, Beasley TM, Adler B. The influence of *CYP2C9* and *VKORC1 1173C/T* genotype on reversal of anticoagulation (INR) following phytonadione administration. *Blood*. 110:3135, 2007.
263. Roseman JM, Go RCP, Acton RT. Genomics and Public Health Prior to the CDC Effort: The linkage of genetic measurements to a Health Risk Assessment. Poster presentation at the 10th Year Anniversary of Public Health Genomics at CDC. January 23, 2008.
264. McLaren CE, Barton JC, McLaren GD, Acton RT, Adams PC, Henkin LF, Gordeuk VR, Eckfeldt JH, Vulpe CD, Harrison BW, Reiss JA, Snively BM. Heritability of Iron Status Phenotype in the Hemochromatosis and Iron Overload Screening (HEIRS) Family Study. *Blood*. 112:115, 2008.
265. Barton J, DelRio-LaFreniere S, Leiendecker-Foster C, Li H, Acton R, Press R, Eckfeldt J. *HFE*, *SLC40A1*, *HAMP*, *HJV*, *TFR2*, and *FTL* mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and *HFE* genotyping in 785 HEIRS study participants. *BioIron*. 2009.
266. McLaren, CE, Garner CP, Constantine CC, Masle S, Vulpe CD, Snively BM, Nickerson DA, Cook JD, Leiendecker-Foster C, Beckman KB, Eckfeldt JH, Gordeuk VR, Barcellos LF, Killeen A, Murray JA, Adams PC, Acton RT, Reboussin DM, Goddard K, McLaren GD. Genome-wide association study of iron deficiency. *BioIron*. 2009.
267. Adams P, Barton J, McLaren G, Acton R, Speechley M, McLaren C, Reboussin , Leiendecker-Foster C, Snively B, Harris E, Vogt T, Sholinsky P, Thomson E, Dawkins F, Gordeuk V, Eckfeldt J. Screening for iron overload: Lessons from the HEIRS study. *BioIron*. 2009.
268. Costa M, Cruz E, Barton J., Thorstensen K, Morais S, Martins da Silva B, Pinto JP, Vieira CP, Carracedo A, Vieira J, Acton RT, Porto G. Conservation of major histocompatibility complex (MHC) haplotypes in *HFE* C282Y homozygous hemochromatosis patients and its effect on the phenotype of low CD8<sup>+</sup> T-lymphocytes: a study in 3 populations from Porto, Alabama and Trondheim. *BioIron*. 2012.

**Books:**

1. **Acton RT**, Lynn JD. (Editors) Cell Culture and Its Application. Academic Press, New York, 1977.
2. Humphrey GB, Dehner LP, Grindey GB, **Acton RT**. (Editors): Pediatric Oncology. Vol 1, Martinus Nijhoff Publishers, The Hague, 1981.

3. Humphrey GB, Dehner LP, Grindey GB, **Acton RT**. (Editors): Pediatric Oncology, Vol 2, Martinus Nijhoff Publishers, The Hague, 1982.
4. Humphrey GB, Grindey G, Dehner LP, **Acton RT**, Pysher TJ. (Editors) Adrenal and Endocrine Tumors in Children, Martinus Nijhoff Medical Publishers, The Hague, 1983.
5. **Acton RT**, Lynn JD. (Editors): Eucaryotic Cell Cultures: Basics and Applications. Plenum Press, New York, 1984.
6. **Acton RT**, Harman LA. Paternity Testing Handbook, The Immunogenetics/DNA Diagnostic Laboratory, University of Alabama Health Services Foundation, Birmingham, Alabama 1988.